var title_f30_14_30944="Renal (kidney) biopsy";
var content_f30_14_30944=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Renal (kidney) biopsy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?30/14/30944/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30944/contributors\" id=\"au1891\">",
"       William L Whittier, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30944/contributors\" id=\"au1890\">",
"       Stephen M Korbet, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?30/14/30944/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30944/contributors\" id=\"se49\">",
"       Richard J Glassock, MD, MACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?30/14/30944/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30944/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?30/14/30944?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     A renal biopsy, also called a kidney biopsy, is a procedure that is used to obtain small pieces of kidney tissue to look at under a microscope. It may be done to determine the cause, severity, and possible treatment of a kidney disorder. The procedure is generally safe and can provide valuable information about your kidney disease.",
"    </p>",
"    <p>",
"     This article discusses why you might need a renal biopsy, how to prepare for it, and what complications might occur. More detailed information about renal biopsy is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=see_link\">",
"      \"Indications for and complications of renal biopsy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      REASONS FOR RENAL BIOPSY",
"     </span>",
"    </p>",
"    <p>",
"     A renal biopsy is recommended for certain people with kidney disease. It may be performed when other blood and urine tests cannot give enough information. The following are the most common reasons for kidney biopsy. You may have one or more of these problems, but not everyone with these problems needs a renal biopsy.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Blood in the urine (called hematuria). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=see_link\">",
"        \"Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Protein in the urine (called proteinuria) occurs in many people with kidney problems. A renal biopsy may be recommended if you have high or increasing levels of protein in the urine or if you have proteinuria along with other signs of kidney disease. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=see_link\">",
"        \"Patient information: Protein in the urine (proteinuria) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Problems with kidney function &mdash; If your kidneys suddenly or slowly stop functioning normally, a renal biopsy may be recommended, especially if the cause of your kidney problem is unclear.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      RENAL BIOPSY PROCEDURE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Preparation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Before your biopsy, you may need testing to see if you have a blood clotting abnormality or infection. To decrease the risk of bleeding, you should stop taking medicines that increase the risk of bleeding (such as aspirin, aspirin-like compounds, ibuprofen, or naproxen) for one to two weeks before the biopsy. Review your medicines with your healthcare provider to determine which ones are safe to continue.",
"    </p>",
"    <p>",
"     If you take warfarin (Coumadin&reg;), heparin, clopidogrel (Plavix&reg;) or other medicines that prevent blood clots, ask your physician when to take these medications before your biopsy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Biopsy procedure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Renal biopsy is usually performed while you are awake, after a cleansing agent is applied, and you are given local anesthesia (numbing medicine) to minimize pain. The most common way to perform a biopsy is to use a needle, which is inserted through the skin and into the kidney.",
"    </p>",
"    <p>",
"     In most cases, you will have an ultrasound, x-ray, or CT scan so that the physician knows exactly where to insert the needle. Once the needle is in the right position, the physician will take a sample of tissue from the kidney with the needle.",
"    </p>",
"    <p>",
"     In some cases, a different approach is used to perform the biopsy. An open renal biopsy involves sedating you with general anesthesia, and making a small cut in your skin, which is opened to obtain the kidney tissue.",
"    </p>",
"    <p>",
"     After the biopsy, the kidney tissue will be sent to a laboratory and examined with a microscope. This microscopic examination is looking for scarring, infection, or abnormalities in the kidney tissue. The results of the microscopic exam are usually available within one to two weeks after the biopsy. In urgent situations, the results can be available within a few hours.",
"    </p>",
"    <p>",
"     After an open or needle biopsy, you will be kept in a recovery or an observation unit for several hours to monitor for potential complications, including pain and bleeding. You may have blood drawn or repeat x-rays to monitor for bleeding. In some instances, you could go home after several hours of monitoring. Alternatively, you may be observed in the hospital overnight.",
"    </p>",
"    <p>",
"     Once it is deemed safe for you to go home, you are not to perform any heavy lifting or vigorous exercise for one to two weeks. You should continue to avoid aspirin-like drugs or blood thinning medications for at least one week or until your physician has instructed you that it is safe to take these.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      RENAL BIOPSY COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Serious complications of renal biopsy are not common. Less serious complications can occur, and can include bleeding, pain, and development of an abnormal connection between two blood vessels (a fistula). Rare complications include infection, damage to blood vessels or other organs, or urine leaks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bleeding is the most common complication of renal biopsy. Many people may notice blood in their urine for several days after a renal biopsy. More severe bleeding occurring around the kidney or into the urine is uncommon but if it occurs you may need a blood transfusion. Very rarely, it may become life threatening and possibly require a procedure or surgery to stop the bleeding. If your urine is bright red or brown for longer than one week after your biopsy, call your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pain is a common problem after a renal biopsy. You can be given medications to reduce pain after the procedure, and the pain usually resolves within a few hours. If you have severe or prolonged pain, call your healthcare provider immediately.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Arteriovenous fistula",
"     </span>",
"     &nbsp;&mdash;&nbsp;The biopsy needle can accidentally injure the walls of a nearby artery and vein, and this can lead to the development of a fistula (a connection between the two blood vessels). Fistulas generally do not cause problems and usually close on their own over time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112942807\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1943006\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/15/27889?source=see_link\">",
"      Patient information: Granulomatosis with polyangiitis (Wegener&rsquo;s) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1943023\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=see_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=see_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112942793\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=see_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=see_link\">",
"      Indications for renal biopsy in patients with lupus nephritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11330?source=see_link\">",
"      Renal pathology test: Case presentations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2035?source=see_link\">",
"      Renal pathology test: Pattern recognition",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/003907.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/003907.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidney.niddk.nih.gov/kudiseases/pubs/biopsy/\">",
"      file://kidney.niddk.nih.gov/kudiseases/pubs/biopsy/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/\">",
"      www.kidney.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?30/14/30944/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?30/14/30944?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30944/abstract/1\">",
"      Fuiano G, Mazza G, Comi N, et al. Current indications for renal biopsy: a questionnaire-based survey. Am J Kidney Dis 2000; 35:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30944/abstract/2\">",
"      Whittier WL, Korbet SM. Renal biopsy: update. Curr Opin Nephrol Hypertens 2004; 13:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30944/abstract/3\">",
"      Lin WC, Yang Y, Wen YK, Chang CC. Outpatient versus inpatient renal biopsy: a retrospective study. Clin Nephrol 2006; 66:17.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f30_14_30944=[""].join("\n");
var outline_f30_14_30944=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           REASONS FOR RENAL BIOPSY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           RENAL BIOPSY PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           RENAL BIOPSY COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f30_14_30945="Proximal phalanx distal fracture";
var content_f30_14_30945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Fracture of the distal portion of the proximal phalanx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radiographs reveal a nondisplaced, nonangulated fracture (white arrow) of the proximal phalanx that does not appear to involve the proximal interphalangeal joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30945=[""].join("\n");
var outline_f30_14_30945=null;
var title_f30_14_30946="Patient information: Treatment choices for angina (chest pain) (The Basics)";
var content_f30_14_30946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86379\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/60/37826\">",
"         Angina",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/38/24175\">",
"          Heart stent",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/7/38004\">",
"           Coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/53/35667\">",
"         Patient information: Cardiac catheterization (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/34/21027\">",
"         Patient information: Chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/27/21940\">",
"         Patient information: Medicines after a heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/35/1587\">",
"         Patient information: Medicines for angina (chest pain) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/1/31766\">",
"         Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/10/43170\">",
"         Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Treatment choices for angina (chest pain) (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H94378109\">",
"      <span class=\"h1\">",
"       What is angina?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Angina is the medical term for chest pain or discomfort that is caused by a condition called &ldquo;coronary heart disease.&rdquo; In this disease, fatty deposits build up in the arteries that supply the heart with blood. When that happens, the arteries narrow, and the heart muscle does not get enough blood. This causes chest pain or discomfort, especially when you do physical activity (",
"      <a class=\"graphic graphic_figure graphicRef78029 \" href=\"UTD.htm?36/60/37826\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94378126\">",
"      <span class=\"h1\">",
"       What are the treatment choices for angina (chest pain)?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are 2 main types of treatment for angina. They are:",
"     </p>",
"     <p>",
"      <strong>",
"       Medical treatment",
"      </strong>",
"      &ndash; This includes different types of medicine, such as &ldquo;nitrates&rdquo; and &ldquo;beta blockers.&rdquo; These medicines work by relaxing blood vessels going to the heart muscle or reducing the amount of work the heart muscle has to do.",
"     </p>",
"     <p>",
"      If you have heart disease, you will also need to take other medicines, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines called statins, which lower cholesterol",
"       </li>",
"       <li>",
"        Medicines to lower blood pressure",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         Aspirin",
"        </a>",
"        or other medicines that help prevent blood clots",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also make these lifestyle changes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Quit smoking, if you smoke.",
"       </li>",
"       <li>",
"        Eat lots of fruits and vegetables and low-fat dairy products, but not a lot of meat or fatty foods.",
"       </li>",
"       <li>",
"        Walk or do some form of physical activity on most days of the week.",
"       </li>",
"       <li>",
"        Lose weight, if you are overweight.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94378160\">",
"      <span class=\"h1\">",
"       Procedures",
"      </span>",
"      &nbsp;&mdash;&nbsp;These restore blood flow to the part of the heart that is not getting enough blood. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Angioplasty and stenting &ndash; During this procedure, the doctor puts a thin tube (called a &ldquo;catheter&rdquo;) into a blood vessel in the leg or arm and moves it to the clogged artery in the heart (",
"        <a class=\"graphic graphic_figure graphicRef78029 \" href=\"UTD.htm?36/60/37826\">",
"         figure 1",
"        </a>",
"        ). Then the doctor inflates a tiny balloon inside the clogged artery to open it. In most people, the doctor props open the artery using a tiny mesh tube called a stent (",
"        <a class=\"graphic graphic_figure graphicRef86256 \" href=\"UTD.htm?23/38/24175\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Bypass surgery (also known as &ldquo;coronary artery bypass grafting&rdquo;) &ndash; During bypass surgery, the doctor removes a healthy piece of blood vessel from another part of the body. Then he or she reattaches this piece of blood vessel above and below the area that is clogged. This re-routes blood around the clogged artery, and allows it to get to the part of the heart that was not getting blood (",
"        <a class=\"graphic graphic_figure graphicRef73589 \" href=\"UTD.htm?37/7/38004\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For relieving angina, either 1 of these procedures might be better than medical treatment alone. But people who have them must still take medicines. In fact, skipping medicines after these procedures can be very dangerous.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94378253\">",
"      <span class=\"h1\">",
"       How do I know which treatment is best for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will help you decide which treatment is best for you. Many different factors affect the decision. These factors include your age, your symptoms, and the results of certain heart tests.",
"     </p>",
"     <p>",
"      If your doctor recommends angioplasty and stenting or bypass surgery, ask these questions:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How might this procedure help me?",
"       </li>",
"       <li>",
"        Will it help me live longer?",
"       </li>",
"       <li>",
"        Will it reduce my chance of having a heart attack?",
"       </li>",
"       <li>",
"        Will I feel better if I have this procedure than I would with medicines alone?",
"       </li>",
"       <li>",
"        What are the risks of the procedure?",
"       </li>",
"       <li>",
"        What happens if I don&rsquo;t have this procedure?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94378270\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=see_link\">",
"       Patient information: Cardiac catheterization (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=see_link\">",
"       Patient information: Chest pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/35/1587?source=see_link\">",
"       Patient information: Medicines for angina (chest pain) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/27/21940?source=see_link\">",
"       Patient information: Medicines after a heart attack (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/1/31766?source=see_link\">",
"       Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=see_link\">",
"       Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?30/14/30946?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86379 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.236-33BC93883C-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30946=[""].join("\n");
var outline_f30_14_30946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94378109\">",
"      What is angina?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94378126\">",
"      What are the treatment choices for angina (chest pain)?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94378160\">",
"      Procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94378253\">",
"      How do I know which treatment is best for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94378270\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86379\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/60/37826\">",
"      Angina",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/38/24175\">",
"       Heart stent",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/7/38004\">",
"        Coronary artery bypass graft surgery",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/1/31766?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=related_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/27/21940?source=related_link\">",
"      Patient information: Medicines after a heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/35/1587?source=related_link\">",
"      Patient information: Medicines for angina (chest pain) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_14_30947="Clocortolone: Patient drug information";
var content_f30_14_30947=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clocortolone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23139?source=see_link\">",
"     see \"Clocortolone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cloderm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cloderm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701832",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clocortolone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12252 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-1401E7A8BA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30947=[""].join("\n");
var outline_f30_14_30947=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152879\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152880\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024918\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024917\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024922\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024923\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024925\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024920\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024921\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024926\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024927\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23139?source=related_link\">",
"      Clocortolone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_14_30948="Bismuth: Pediatric drug information";
var content_f30_14_30948=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bismuth: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"    see \"Bismuth: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/44/29380?source=see_link\">",
"    see \"Bismuth: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bismatrol Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Bismatrol [OTC];",
"     </li>",
"     <li>",
"      Diotame [OTC];",
"     </li>",
"     <li>",
"      Kao-Tin [OTC];",
"     </li>",
"     <li>",
"      Kaopectate&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Kaopectate&reg; [OTC];",
"     </li>",
"     <li>",
"      Peptic Relief [OTC];",
"     </li>",
"     <li>",
"      Pepto Relief [OTC];",
"     </li>",
"     <li>",
"      Pepto-Bismol&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Pepto-Bismol&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiarrheal",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"      see \"Bismuth: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Bismuth subsalicylate:",
"     <b>",
"      (bismuth subsalicylate liquid dosages expressed in mL of 262 mg/15 mL concentration):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nonspecific diarrhea: Children: 100 mg/kg/day divided into 5 equal doses for 5 days (maximum: 4.19 g/day)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Up to 8 doses/24 hours:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     3-6 years:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     tablet or 5 mL (87 mg) every 30 minutes to 1 hour as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-9 years:",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     tablet or 10 mL (175 mg) every 30 minutes to 1 hour as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-12 years: 1 tablet or 15 mL (262 mg) every 30 minutes to 1 hour as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2 tablets or 30 mL (524 mg) every 30 minutes to 1 hour as needed up to 8 doses/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chronic infantile diarrhea:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-24 months: 2.5 mL (44 mg) every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     24-48 months: 5 mL (87 mg) every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     48-70 months: 10 mL (175 mg) every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of traveler's diarrhea: Adults: 2.1 g/day or 2 tablets 4 times/day before meals and at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     -associated antral gastritis: Dosage in children is not well established, the following dosages have been used [in conjunction with ampicillin and metronidazole or (in adults) tetracycline and metronidazole]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &le;10 years: 15 mL (262 mg) 4 times/day for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;10 years and Adults: 30 mL (524 mg) solution or two 262 mg tablets 4 times/day for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Avoid use in patients with renal failure",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F141504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral, as subsalicylate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto-Bismol&reg;: 262 mg [sugar free; contains sodium 2 mg/caplet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as subsalicylate: 262 mg/15 mL (120 mL, 240 mL, 360 mL, 480 mL); 525 mg/15 mL (240 mL, 360 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bismatrol: 262 mg/15 mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bismatrol Maximum Strength: 525 mg/15 mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diotame: 262 mg/15 mL (30 mL) [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kao-Tin: 262 mg/15 mL (240 mL, 473 mL) [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaopectate&reg;: 262 mg/15 mL (236 mL) [contains potassium 5 mg/15 mL, sodium 5 mg/15 mL; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaopectate&reg;: 262 mg/15 mL (177 mL) [contains sodium 4 mg/15 mL; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaopectate&reg;: 262 mg/15 mL (236 mL, 354 mL) [contains sodium 4 mg/15 mL; vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaopectate&reg; Extra Strength: 525 mg/15 mL (236 mL) [contains potassium 5 mg/15 mL, sodium 5 mg/15 mL; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peptic Relief: 262 mg/15 mL (237 mL) [sugar free; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto-Bismol&reg;: 262 mg/15 mL (240 mL, 360 mL, 480 mL) [sugar free; contains benzoic acid, sodium 6 mg/15 mL; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto-Bismol&reg;: 262 mg/15 mL (120 mL, 240 mL, 360 mL, 480 mL) [sugar free; contains benzoic acid, sodium 6 mg/15 mL; wintergreen flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto-Bismol&reg; Maximum Strength: 525 mg/15 mL (120 mL, 240 mL, 360 mL) [sugar free; contains benzoic acid, sodium 6 mg/15 mL; wintergreen flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as subsalicylate: 262 mg/15 mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as subsalicylate: 262 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bismatrol: 262 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diotame: 262 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peptic Relief: 262 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto Relief: 262 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto-Bismol&reg;: 262 mg [sugar free; contains sodium &lt;1 mg/tablet; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto-Bismol&reg;: 262 mg [sugar free; contains sodium &lt;1 mg/tablet; wintergreen flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F141491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Shake liquid well before using; chew tablets or allow to dissolve in mouth before swallowing",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Subsalicylate formulation: Symptomatic treatment of mild, nonspecific diarrhea including traveler's diarrhea; chronic infantile diarrhea; adjunctive treatment of",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     -associated antral gastritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Subgallate formulation: An aid to reduce fecal odors from a colostomy or ileostomy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F141546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kaopectate&reg; may be confused with Kayexalate&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Maalox&reg; Total  Relief&reg; is a different formulation than other Maalox&reg; liquid antacid products which contain aluminum hydroxide, magnesium hydroxide, and simethicone.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Canadian formulation of Kaopectate&reg; does not contain bismuth; the active ingredient in the Canadian formulation is attapulgite.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F141544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Subsalicylate formulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, confusion, headache, mental depression, slurred speech",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Discoloration of the tongue (darkening), grayish black stools, impaction may occur in infants and debilitated patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasms, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss, tinnitus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bismuth, salicylates, or any component; history of severe GI bleeding or coagulopathy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May interfere with radiologic examinations of GI tract as bismuth is radiopaque; should not be used in patients with a history of bleeding disorder, gastrointestinal ulcer disease, or those taking anticoagulants, clopidogrel, NSAIDS, and/or oral antidiabetic agents.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Kaopectate&reg; has been reformulated to contain",
"     <b>",
"      only",
"     </b>",
"     bismuth subsalicylate; follow dosage recommendations closely. Do not use subsalicylate in patients with a viral infection, such as influenza or chickenpox, because of the risk of Reye's syndrome; when using bismuth subsalicylate, changes in behavior (along with nausea and vomiting) may be an early sign of Reye's syndrome; instruct patients and caregivers to contact their healthcare provider if these symptoms occur; subsalicylate should be used with caution if patient is taking aspirin, due to additive toxicity; use with caution in children &lt;3 years of age; be aware of salicylate content when prescribing for use in children. May cause bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F141499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Bismuth may decrease the serum concentration of Tetracycline Derivatives.  Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13755164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following oral administration, bismuth and salicylates cross the placenta. The use of salicylates in pregnancy may adversely affect the newborn (Lione, 1988). Use during pregnancy is not recommended (Mahadevan, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adsorbs extra water in large intestine, as well as toxins; forms a protective coat on the intestinal mucosa; appears to have antisecretory (salicylate moiety) and antimicrobial effects (bismuth moiety) against bacterial and viral pathogens",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Bismuth is minimally absorbed (&lt;1%) across the GI tract while salicylate salt is readily absorbed (80%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Salicylate: V",
"     <sub>",
"      d",
"     </sub>",
"     : 170 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: Bismuth and salicylate: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Bismuth salts undergo chemical dissociation after oral administration; salicylate is extensively metabolized in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bismuth: Terminal: 21-72 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Salicylate: Terminal: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bismuth: Renal, biliary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Salicylate: Only 10% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/44/29380?source=see_link\">",
"      see \"Bismuth: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May darken stools; if diarrhea persists for more than 2 days, consult a physician; may turn tongue black; notify physician if behavioral changes along with nausea and vomiting occur",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bismuth subsalicylate: 262 mg = 130 mg nonaspirin salicylate; 525 mg = 236 mg nonaspirin salicylate",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Drumm B, Sherman P, Karmali M, et al, &ldquo;Treatment of",
"      <i>",
"       Campylobacter pylori",
"      </i>",
"      -associated Antral Gastritis in Children With Bismuth Subsalicylate and Ampicillin,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1988, 113(5):908-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30948/abstract-text/3183851/pubmed\" id=\"3183851\" target=\"_blank\">",
"        3183851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soriano-Brucher HE, Avendano P, O'Ryan M, et al, &ldquo;Use of Bismuth Subsalicylate in Acute Diarrhea in Children,&rdquo;",
"      <i>",
"       Rev Infect Dis",
"      </i>",
"      , 1990, 12(Suppl 1):S51-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30948/abstract-text/2406856 /pubmed\" id=\"2406856 \" target=\"_blank\">",
"        2406856",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh JH and Peterson WL, &ldquo;The Treatment of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection in the Management of Peptic Ulcer Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(15):984-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30948/abstract-text/7666920/pubmed\" id=\"7666920\" target=\"_blank\">",
"        7666920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13261 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-E01451B0F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30948=[""].join("\n");
var outline_f30_14_30948=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141521\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056882\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056876\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141504\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141491\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056885\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056884\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141546\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141544\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056888\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056875\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056874\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298868\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141499\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13755164\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056873\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056887\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056881\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056889\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13261\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13261|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=related_link\">",
"      Bismuth: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/44/29380?source=related_link\">",
"      Bismuth: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_14_30949="Iohexol: Drug information";
var content_f30_14_30949=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iohexol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/25/13716?source=see_link\">",
"    see \"Iohexol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Omnipaque&trade; 140 [DSC];",
"     </li>",
"     <li>",
"      Omnipaque&trade; 180;",
"     </li>",
"     <li>",
"      Omnipaque&trade; 240;",
"     </li>",
"     <li>",
"      Omnipaque&trade; 300;",
"     </li>",
"     <li>",
"      Omnipaque&trade; 350",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9617644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Omnipaque&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iodinated Contrast Media;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Nonionic, Low Osmolality)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7983659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing is based numerous variables including: type of examination, route of administration, patient age/weight and product. Consult specific product information for detailed dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7983658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing is based numerous variables including: type of examination, route of administration, patient age/weight and product. Consult specific product information for detailed dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15962260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use caution in severe impairment and in setting of combined renal and hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15962261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use caution in patients with combined hepatic and renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnipaque&trade; 140: 302 mg/mL (50 mL [DSC]) [contains edetate calcium disodium; provides organic iodine 140 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnipaque&trade; 180: 388 mg/mL (10 mL, 20 mL) [contains edetate calcium disodium; provides organic iodine 180 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnipaque&trade; 240: 518 mg/mL (10 mL, 20 mL, 50 mL, 75 mL [DSC], 100 mL, 150 mL, 200 mL) [contains edetate calcium disodium; provides organic iodine 240 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnipaque&trade; 300: 647 mg/mL (10 mL, 30 mL, 50 mL, 75 mL, 100 mL, 125 mL, 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium; provides organic iodine 300 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnipaque&trade; 350: 755 mg/mL (50 mL, 75 mL, 100 mL, 125 mL, 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium; provides organic iodine 350 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7983660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Withdrawal of contrast agents from container should be completed with aseptic technique. Intrathecal doses should be administered slowly over 1-2 minutes to avoid excessive mixing with CSF through a lumbar needle under fluoroscopic control. Intravenous doses should be at body temperature prior to administration. In angiography, use meticulous intravascular administration technique to minimize thrombotic events including use of plastic syringes, frequent catheter flushing, and close attention to catheter and guide wire manipulation.",
"     <b>",
"      Note:",
"     </b>",
"     Omnipaque&trade; 140, and 350 are",
"     <b>",
"      not",
"     </b>",
"     for intrathecal use; Rediflo&trade; prefilled cartridges are",
"     <b>",
"      not",
"     </b>",
"     for intrathecal use; caution should be used during product selection.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F13796664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Fenoldopam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Ampicillin, bupivacaine, chloramphenicol, cimetidine, diphenhydramine, epinephrine, gentamicin, heparin, hydrocortisone sodium succinate, methylprednisolone sodium succinate, papaverine, protamine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrathecal: Myelography; contrast enhancement for computerized tomography",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intravascular: Angiocardiography, aortography, digital subtraction angiography, peripheral arteriography, excretory urography; contrast enhancement for computed tomographic imaging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral/body cavity: Arthrography, GI tract examination, hysterosalpingography, pancreatography, cholangiopancreatography, herniography, cystourethrography; enhanced computed tomography of the abdomen",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7983646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined;",
"     <b>",
"      Note:",
"     </b>",
"     Children have a lower frequency of reactions than adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Asystole, arrhythmia, bradycardia, cardiopulmonary collapse, edema, heart failure, hypertension (in patients with phenochromocytoma after intra-arterial injection), hypotension, syncope, transient ischemic attacks, vasovagal attacks, venous thrombosis, ventricular fibrillation, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Anxiety, confusion, dizziness, headache, loss of consciousness, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Thyrotoxicosis exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Cramping, diarrhea, nausea, salivary gland swelling, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Burning sensation, pain at injection site, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Parasthesia, polyarthropathy, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Vision abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Contrast-associated nephropathy, creatinine increased, renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Bronchospasm, cough, dyspnea, pulmonary edema, rhinitis, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylactoid reaction, diaphoresis, hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F183885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iohexol or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Intrathecal iohexol: Use is contraindicated with concurrent intrathecal corticosteroid administration; significant bacterial infection; concentrations 140 and 350, and Rediflo&trade; prefilled cartridges are not for intrathecal use",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7983643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Allergic reactions: Use extreme caution with history of previous reaction to contrast dye, iodine-based contrast media or patients with a known clinical hypersensitivity (eg. bronchial asthma, hay fever or food allergies). Premedication with antihistamines or corticosteroids can be considered to reduce incidence and severity of reaction. Severe, potentially life-threatening reactions and delayed reactions may occur. Monitor closely after injection. Must be administered in a setting where staff is familiar with the recognition and treatment of allergic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Contrast-associated nephropathy: Patients should be well hydrated before and after examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Seizures: Caution in patients with history of epilepsy; focal and generalized motor seizures have been reported when higher than recommended doses used; antiepileptic therapy should be continued. Prophylactic anticonvulsant therapy should be considered in patients requiring a concentrated solution or large bolus of contrast media. CNS-acting agents, primarily those which lower seizure threshold (eg, phenothiazines, MAO inhibitors, tricyclic antidepressants, SSRIs), should be discontinued 24-72 hours prior to intrathecal use and not resumed for 24 hours post procedure (ACR, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thromboembolism: Serious, rarely fatal, thromboembolic events causing myocardial infarction (MI) and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Ionic iodinated contrast media may inhibit blood coagulation. Use meticulous intravascular administration techniques during angiographic procedures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use caution in severe cardiovascular disease and heart failure; transitory increase in circulatory osmotic load could occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Chronic alcoholism: Use caution in patients with alcoholism taking metformin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatorenal insufficiency: Use caution in hepatorenal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperthyroidism: Reports of thyroid storm following administration of iodinated contrast media have been reported in patients with hyperthyroidism or with an autonomously functioning thyroid nodule.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Multiple myeloma: Use with caution in multiple myeloma; use of intravascular contrast agents may lead to renal dysfunction, especially with concurrent dehydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pheochromocytoma: Use extreme caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal disease: Use caution in renal disease. May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in diabetics, elderly, advanced vascular disease, and those who are dehydrated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sickle cell disease: Use caution in homozygous sickle cell patients; administration of contrast media may result in disease exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Intrathecal administration: Inadvertent administration of iodinated contrast media that is not indicated for intrathecal use has resulted in serious adverse events. Precautions should be taken to ensure iohexol concentrations 140 and 350 are",
"     <b>",
"      not",
"     </b>",
"     administered intrathecally; Rediflo&trade; prefilled cartridges are",
"     <b>",
"      not",
"     </b>",
"     for intrathecal use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Oral solution administration: Hypertonic contrast media can draw fluid into the intestinal lumen causing plasma fluid loss and diarrhea; with severe loss hypovolemia results and in some cases a shock-like state.  Elderly, cachectic patients, children, and infants are especially susceptible.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Contrast Media (Non-ionic) may enhance the potential for allergic or hypersensitivity reactions to Aldesleukin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F183880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F183887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal harm was not observed in animal studies. In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F183892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F183888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A very small percentage of iodinated contrast medium is excreted into breast milk. The expected dose absorbed by the infant from breast milk is &lt;0.01% (&lt;1% of the dose an infant would receive if undergoing an imaging study). American College of Radiology (ACR) suggests that it is safe for mother and infant to continue breast-feeding after mother receives a contrast medium (ACR, 2008). If mother remains concerned, bottle feedings of previously expressed breast milk are recommended for 24 hours after contract administration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Omnipaque Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg/mL (10 mL): $56.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg/mL (50 mL): $45.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/mL (50 mL): $55.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Omnipaque Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     140 mg/mL (50 mL): $40.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     350 mg/mL (50 mL): $60.42",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F183889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hexosure (KP);",
"     </li>",
"     <li>",
"      Iobrix (KP, TH);",
"     </li>",
"     <li>",
"      Medixol 350 (PE);",
"     </li>",
"     <li>",
"      Omnipaque (AT, AU, BE, BG, CH, CL, CN, CO, CZ, DE, DK, EE, FI, FR, GB, GR, HN, IE, IL, IT, NL, NO, NZ, PL, PT, PY, RU, SE, SG, TR, UY, VE);",
"     </li>",
"     <li>",
"      Radiopaque (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7983651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Opacification of vessels and anatomical structures in the path of flow of the contrast media which allows for radiographic visualization",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7983653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CNS: ~30 minutes following intrathecal administration, 60 minutes following intravenous administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Serum: 15-120 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (80% to 90% unchanged)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Obstetric Practice, &ldquo;ACOG Committee Opinion. Guidelines for Diagnostic Imaging During Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 104(3):647-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30949/abstract-text/15339791/pubmed\" id=\"15339791\" target=\"_blank\">",
"        15339791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Radiology, &ldquo;Manual on Contrast Media, Version 7.0&rdquo;, 2010. Available at file://gm.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Radiology, &ldquo;Practice Guideline for the Performance of Myelography and Cisternography,&rdquo; Available at file://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/dx/head-neck/myelography.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30949/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein LW, Sheldon MW, Brinker J, et al, &ldquo;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Catheter Cardiovasc Interv",
"      </i>",
"      , 2009, 74(4):728-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30949/abstract-text/19830793/pubmed\" id=\"19830793\" target=\"_blank\">",
"        19830793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laskey WK, Jenkins C, Selzer F, et al, &ldquo;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):584-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30949/abstract-text/17692741/pubmed\" id=\"17692741\" target=\"_blank\">",
"        17692741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30949/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8927 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9089A68DA0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30949=[""].join("\n");
var outline_f30_14_30949=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183891\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9617644\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183894\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983659\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983658\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962260\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962261\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183882\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183878\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983660\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13796664\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183883\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174548\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983646\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183885\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983643\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299530\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221091\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183880\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183887\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183892\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183888\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323204\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183889\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983651\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983653\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8927\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8927|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/25/13716?source=related_link\">",
"      Iohexol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_14_30950="Acute coronary syndromes in pregnancy";
var content_f30_14_30950=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute coronary syndromes in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/14/30950/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30950/contributors\">",
"     Carol A Waksmonski, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30950/contributors\">",
"     Anita LaSala, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/14/30950/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30950/contributors\">",
"     Guy S Reeder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30950/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/14/30950/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30950/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/14/30950/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although myocardial infarction (MI) is a rare event in women of childbearing age, some studies have suggested an increased risk during pregnancy and in the early postpartum period. Issues related to acute MI in pregnancy will be reviewed here. Other types of acquired heart disease in pregnancy, such as valvular disease and heart failure, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link\">",
"     \"Acquired heart disease and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link\">",
"     \"Management of heart failure in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency and timing of acute MI associated with pregnancy can be illustrated by the findings in two large epidemiologic studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from California of births between 1991 and 2000, there were 151 cases with a diagnosis of acute MI, resulting in an incidence of 2.8 per 100,000 deliveries [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a review from the Nationwide Inpatient Sample of pregnancy discharges between 2000 and 2002 in about 1000 hospitals in the United States, there were 859 discharges that included a diagnosis of acute MI, resulting in an incidence of 6.2 in 100,000 pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/2\">",
"       2",
"      </a>",
"      ]. It was estimated the risk of MI was increased three- to fourfold compared to nonpregnant women. Possible explanations for the increased rate of MI compared to the earlier report from the California database include regional differences, improved detection due to widespread use of troponins, and an increased number of pregnancies in older women, who are at greater risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study from the United Kingdom, ischemic heart disease was the most common cause of cardiac disease leading to maternal death [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases occur in the third trimester and six-week postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The infarction commonly involves the anterior wall [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four major risk factors for acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older maternal age (age &gt;35 years)",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The magnitude of the increase in risk was evaluated in the series of 859 cases from the Nationwide Inpatient Sample [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/2\">",
"     2",
"    </a>",
"    ]. In a multivariable regression model, the odds ratio was 21.7 for hypertension and 3.6 for diabetes. Age &ge;30 years was also an independent risk factor and the odds ratio was 6.7 between the ages of 30 and 34, and 15 to 16 at &ge;35 years of age.",
"   </p>",
"   <p>",
"    Other independent risk factors in this report were smoking (odds ratio 8.4) thrombophilia, including a history of thrombosis and antiphospholipid syndrome (odds ratio 25.6), and pregnancy complications such as blood transfusion, and postpartum infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/2\">",
"     2",
"    </a>",
"    ]. The marked increase in risk with thrombophilia may reflect an interaction with the hypercoagulable state induced by pregnancy.",
"   </p>",
"   <p>",
"    It is not clear if pregnancy itself is a risk factor for MI. In a report that had 3.6 million woman-years of observation, the incidence of a first-ever MI not related to pregnancy was 5.0 per 100,000 woman-years in women of child-bearing age, with the risk increasing dramatically after age 35 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/6\">",
"     6",
"    </a>",
"    ]. Since pregnancy lasts three-quarters of a year, this rate of MI is not different from the rates in the two large epidemiologic studies cited above (2.8 to 6.2 per 100,000 pregnancies) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Coronary artery morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a review of 103 cases from 1995 to 2005, coronary artery morphology was evaluated in 96 by arteriography or autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/7\">",
"     7",
"    </a>",
"    ]. Coronary atherosclerosis with or without intracoronary thrombus was present in only 40 percent. The remaining cases consisted of thrombus in a normal coronary artery (8 percent), coronary artery dissection (27 percent), spasm in (2 percent), emboli (2 percent), and normal coronary arteries (13 percent).",
"   </p>",
"   <p>",
"    It has been suggested that arterial dissection during or early after pregnancy is related to structural changes in the intima and media of the arterial wall that are produced by hormonal and hemodynamic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Although dissection can occur in the absence of risk factors, it may occur more frequently in conditions associated with hypertension that independently damage the arterial wall. The finding of spontaneous coronary artery dissection should trigger the search for a previously undiagnosed connective tissue disease, such as Ehler-Danlos syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and treatment of the hypermobility syndrome\", section on 'Ehlers-Danlos syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The susceptibility to coronary artery dissection may explain why hypertension was such an important risk factor for MI in the Nationwide Inpatient Sample [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41113?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features and diagnosis of coronary heart disease in women\", section on 'Spontaneous coronary artery dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute MI associated with pregnancy is mostly guided by the same principles as in the general population, including ischemic symptoms (eg, anginal chest pain), ECG changes, and elevations in cardiac biomarkers [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/9\">",
"     9",
"    </a>",
"    ]. In terms of cardiac biomarkers, troponins are preferred to CK-MB and troponin I may be the marker of choice in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of acute MI is also generally similar, including the use of revascularization with percutaneous coronary intervention (PCI) and stenting or coronary artery bypass graft surgery (CABG) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/2,9,11-13\">",
"     2,9,11-13",
"    </a>",
"    ]. In the series from the Nationwide Inpatient Sample of 859 cases seen between 2000 and 2002, cardiac catheterization was performed in 45 percent and PCI or CABG in 37 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, some unique considerations in pregnant women with a myocardial infarction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fetus should be closely monitored with a plan for delivery if there is sudden maternal or fetal deterioration. In the event of maternal cardiac arrest, the best prognosis for the fetus occurs when delivery is within four to five minutes. Delivery may also aid maternal resuscitative efforts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22569?source=see_link&amp;anchor=H15#H15\">",
"       \"Trauma in pregnancy\", section on 'Cesarean delivery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      &mdash; Low dose aspirin (75 to 162",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      appears to be safe in pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      &mdash; Most patients with recent acute coronary syndrome require clopidogrel (or other platelet P2Y12 receptor blocker). The safety of clopidogrel in human pregnancy has not been established, but data from animal studies did not show an increase in adverse reproductive events [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/16\">",
"       16",
"      </a>",
"      ]. The combination of clopidogrel and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      might increase bleeding at the time of delivery.",
"     </li>",
"     <li>",
"      Fibrinolytic therapy &mdash; There are no controlled studies examining the efficacy and safety of fibrinolytic therapy for acute ST-elevation MI in pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. Although teratogenicity has not been reported, the reported risk of maternal hemorrhage is about 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/19\">",
"       19",
"      </a>",
"      ]. The risk of puerperal hemorrhage appears to be confined to women treated within eight hours of delivery, although some women have been safely treated, most with disorders other than acute MI [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/18,20-22\">",
"       18,20-22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anticoagulation &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      does not cross the placenta and thus does not affect the fetus directly, but pregnancy complications associated with bleeding (eg, threatened miscarriage, placenta previa, abruptio placenta) are more problematic in a woman who is anticoagulated. In such patients, heparin may have to be discontinued until the bleeding has resolved. In addition, heparin should be discontinued during labor to minimize maternal bleeding complications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"       \"Anticoagulation during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In women who receive an intracoronary stent, we prefer bare metal stents. The safety of drug-eluting stents is unknown.",
"     </li>",
"     <li>",
"      Nitrates &mdash; Intravenous, transdermal, and oral nitrates have been used during pregnancy for both obstetric and medical indications without apparent harmful effects, although maternal hypotension should be avoided [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24566?source=see_link\">",
"       \"Nitrates in the management of acute coronary syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=see_link\">",
"       \"Nitrates in the management of stable angina pectoris\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beta blockers &mdash; Beta blockers are generally safe for pregnant women. However, occasional cases of neonatal growth restriction, hypoglycemia, respiratory depression, and bradycardia have been reported after maternal administration of beta blockers, particularly with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       Labetalol",
"      </a>",
"      may be the preferred beta blocker. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"       \"Management of hypertension in pregnant and postpartum women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ACE inhibitors and statins &mdash; Angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and statins are contraindicated in pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/26\">",
"       26",
"      </a>",
"      ]. Thus, neither class of drugs should be used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"       \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link&amp;anchor=H19#H19\">",
"       \"Statins: Actions, side effects, and administration\", section on 'Risks in pregnancy and breastfeeding'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Labor and delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the increased hemodynamic stress associated with labor, it has been recommended that induction of labor or scheduled cesarean delivery should be delayed, if possible, for at least two to three weeks after an acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/27\">",
"     27",
"    </a>",
"    ]. General issues related to labor and delivery in women with underlying heart disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link&amp;anchor=H18#H18\">",
"     \"Acquired heart disease and pregnancy\", section on 'Management of labor and delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there are no clinical trials that have prospectively evaluated the optimal timing of surgical procedures or labor and delivery after an acute (one to seven days) or recent (7 to 30 days) MI, especially in the current era of cardiac therapies and modern anesthesia. Measures should be taken to minimize the cardiac workload during delivery; these include epidural anesthesia, supplemental oxygen, left lateral position, treatment of hypertension and tachycardia, and either an instrumental vaginal delivery or cesarean birth (in unstable cases or for the usual obstetric indications) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prior MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little information available regarding the risk of pregnancy in women with known ischemic heart disease, a prior history of MI, or prior revascularization with PCI or CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/4,28-30\">",
"     4,28-30",
"    </a>",
"    ]. Counseling these women is based upon a thorough evaluation of their cardiac status, particularly left ventricular function, ongoing myocardial ischemia, and underlying coronary anatomy. Changes in the patient's chronic medical regimen would include cessation of ACE inhibitors and statins, which are contraindicated in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The highest risk for maternal death exists when MI occurs in the late third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. During labor, further cardiac ischemia and decompensation can develop because cardiac demands are maximal at a time when myocardial healing is incomplete.",
"   </p>",
"   <p>",
"    In the two large epidemiologic studies cited above, the in-hospital maternal mortality was 7.3 and 5.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A much higher mortality rate (21 percent) was noted in an earlier study, most often occurring within two weeks of the infarction and usually being related to labor and delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/4\">",
"     4",
"    </a>",
"    ]. The increase in mortality may reflect both the higher mortality in the earlier time period and a bias toward including severe or fatal cases [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24951706\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The European Society of Cardiology has published guidelines for the management of cardiovascular diseases during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30950/abstract/31\">",
"     31",
"    </a>",
"    ]. That document includes the following recommendations for the management of coronary artery disease in pregnant women, with a focus on care at the time of an acute coronary syndrome (ACS):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An electrocardiogram(s) and troponin level(s) should be performed in pregnant women with chest pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"       \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We believe this is a reasonable approach when the managing physicians have a concern that the chest pain is potentially ischemic in origin. Many pregnant women have symptoms of chest pain, but gastroesophageal reflux disease is often the cause.",
"     </li>",
"     <li>",
"      Coronary angioplasty is the preferred reperfusion therapy for patients with ST-elevation myocardial infarction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=see_link\">",
"       \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A conservative strategy should be considered for pregnant women with non-ST elevation ACS without risk criteria, whereas an invasive strategy should be considered for those with risk criteria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link\">",
"       \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction (MI) is a rare event in women of childbearing age, although the risk is increased during pregnancy and in the early postpartum period.",
"   </p>",
"   <p>",
"    Data collected between 2000 and 2002 suggests an incidence of 6.2 in 100,000 pregnancies. Most cases occur in the third trimester and six-week postpartum period. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Risk factors include the traditional coronary heart disease risk factors as well as thrombophilia (including a history of thrombosis and antiphospholipid syndrome) and pregnancy complications such as blood transfusion, and postpartum infection. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis and management of acute MI associated with pregnancy is guided by the same principles as in the general population. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnosis and management'",
"    </a>",
"    above.) However, The following should be kept in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fetus should be closely monitored. There should be a plan for delivery if there is sudden maternal or fetal deterioration.",
"     </li>",
"     <li>",
"      Low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 to 162",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      beta blockers, and nitrates have been used during pregnancy without apparent harmful effects. When the latter two drugs are used, hypotension should be avoided.",
"     </li>",
"     <li>",
"      Pregnancy is a relative contraindication to fibrinolytic therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      does not cross the placenta and thus does not affect the fetus directly. However, pregnancy complications associated with bleeding (eg, threatened miscarriage, placenta previa, abruptio placenta) are more problematic in a woman who is anticoagulated.",
"     </li>",
"     <li>",
"      Angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and statins are contraindicated in pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/1\">",
"      Ladner HE, Danielsen B, Gilbert WM. Acute myocardial infarction in pregnancy and the puerperium: a population-based study. Obstet Gynecol 2005; 105:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/2\">",
"      James AH, Jamison MG, Biswas MS, et al. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation 2006; 113:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/3\">",
"      Roos-Hesselink JW, Duvekot JJ, Thorne SA. Pregnancy in high risk cardiac conditions. Heart 2009; 95:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/4\">",
"      Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. Ann Intern Med 1996; 125:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/5\">",
"      H&auml;rtel D, Sorges E, Carlsson J, et al. [Myocardial infarction and thromboembolism during pregnancy]. Herz 2003; 28:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/6\">",
"      Petitti DB, Sidney S, Quesenberry CP Jr, Bernstein A. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke 1997; 28:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/7\">",
"      Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. J Am Coll Cardiol 2008; 52:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/8\">",
"      Mather PJ, Hansen CL, Goldman B, et al. Postpartum multivessel coronary dissection. J Heart Lung Transplant 1994; 13:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/9\">",
"      Nallamothu BK, Saint M, Saint S, Mukherjee D. Clinical problem-solving. Double jeopardy. N Engl J Med 2005; 353:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/10\">",
"      Shade GH Jr, Ross G, Bever FN, et al. Troponin I in the diagnosis of acute myocardial infarction in pregnancy, labor, and post partum. Am J Obstet Gynecol 2002; 187:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/11\">",
"      Chaithiraphan V, Gowda RM, Khan IA, Reimers CD. Peripartum acute myocardial infarction: management perspective. Am J Ther 2003; 10:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/12\">",
"      Ascarelli MH, Grider AR, Hsu HW. Acute myocardial infarction during pregnancy managed with immediate percutaneous transluminal coronary angioplasty. Obstet Gynecol 1996; 88:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/13\">",
"      Sanchez-Ramos L, Chami YG, Bass TA, et al. Myocardial infarction during pregnancy: management with transluminal coronary angioplasty and metallic intracoronary stents. Am J Obstet Gynecol 1994; 171:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/14\">",
"      Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. Br J Obstet Gynaecol 1995; 102:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/15\">",
"      Hauth JC, Goldenberg RL, Parker CR Jr, et al. Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality. Obstet Gynecol 1995; 85:1055.",
"     </a>",
"    </li>",
"    <li>",
"     www.Reprotox.org (Accessed May 26, 2010). www.Reprotox.org (Accessed on May 26, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/17\">",
"      Schumacher B, Belfort MA, Card RJ. Successful treatment of acute myocardial infarction during pregnancy with tissue plasminogen activator. Am J Obstet Gynecol 1997; 176:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/18\">",
"      Roberts DH, Rodrigues EA, Ramsdale DR. Postpartum acute myocardial infarction successfully treated with intravenous streptokinase--a case report. Angiology 1993; 44:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/19\">",
"      Turrentine MA, Braems G, Ramirez MM. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv 1995; 50:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/20\">",
"      Cincotta RB, Davis SM, Gerraty RP, Thomson KR. Thrombolytic therapy for basilar artery thrombosis in the puerperium. Am J Obstet Gynecol 1995; 173:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/21\">",
"      Fagher B, Ahlgren M, Astedt B. Acute massive pulmonary embolism treated with streptokinase during labor and the early puerperium. Acta Obstet Gynecol Scand 1990; 69:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/22\">",
"      Hall RJ, Young C, Sutton GC, Cambell S. Treatment of acute massive pulmonary embolism by streptokinase during labour and delivery. Br Med J 1972; 4:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/23\">",
"      Lees CC, Lojacono A, Thompson C, et al. Glyceryl trinitrate and ritodrine in tocolysis: an international multicenter randomized study. GTN Preterm Labour Investigation Group. Obstet Gynecol 1999; 94:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/24\">",
"      Rubin PC. Current concepts: beta-blockers in pregnancy. N Engl J Med 1981; 305:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/25\">",
"      Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 1990; 301:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/26\">",
"      Henck JW, Craft WR, Black A, et al. Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats. Toxicol Sci 1998; 41:88.",
"     </a>",
"    </li>",
"    <li>",
"     Cardiac Problems in Pregnancy, 3rd, Elkayam U, Gleicher N (Eds), Wiley-Liss, New York 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/28\">",
"      Pombar X, Strassner HT, Fenner PC. Pregnancy in a woman with class H diabetes mellitus and previous coronary artery bypass graft: a case report and review of the literature. Obstet Gynecol 1995; 85:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/29\">",
"      Vinatier D, Virelizier S, Depret-Mosser S, et al. Pregnancy after myocardial infarction. Eur J Obstet Gynecol Reprod Biol 1994; 56:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/30\">",
"      Frenkel Y, Barkai G, Reisin L, et al. Pregnancy after myocardial infarction: are we playing safe? Obstet Gynecol 1991; 77:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30950/abstract/31\">",
"      European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:3147.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 89 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30950=[""].join("\n");
var outline_f30_14_30950=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Coronary artery morphology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prior MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24951706\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41113?source=related_link\">",
"      Clinical features and diagnosis of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=related_link\">",
"      Clinical manifestations and treatment of the hypermobility syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24566?source=related_link\">",
"      Nitrates in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=related_link\">",
"      Nitrates in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22569?source=related_link\">",
"      Trauma in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_14_30951="Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?";
var content_f30_14_30951=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/14/30951/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30951/contributors\">",
"     W Neal Roberts, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/14/30951/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30951/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/14/30951/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30951/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/14/30951/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review the following material:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The history of intraarticular injections in the treatment of rheumatic diseases",
"     </li>",
"     <li>",
"      Considerations in selection of glucocorticoids and the frequency of injections",
"     </li>",
"     <li>",
"      Investigational approaches to the treatment of rheumatic disorders that involve intraarticular injection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The technique, indications, and complications that can occur with intraarticular and periarticular injections of glucocorticoids, as well as the use of intraarticular hyaluronic acid derivatives, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28564?source=see_link\">",
"     \"Joint aspiration or injection in adults: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraarticular injection of chemicals or short-lived radionuclides, which is sometimes used as an alternative to surgical synovectomy, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28565?source=see_link\">",
"     \"Synovectomy for inflammatory arthritis of the knee\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beginning in the 1930s, efforts at a scientific approach to arthrocentesis and synovial fluid analysis were summarized in two textbooks: 1) Pemberton&rsquo;s first US rheumatology textbook explained the techniques of obtaining synovial fluid in 1935 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/1\">",
"     1",
"    </a>",
"    ], and 2) Ropes&rsquo; book, a compilation of twenty years of clinical experience, which was published in 1953, added information on synovial fluid analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Formalin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    , lipiodol, lactic acid, and petroleum jelly were among the substances injected into joints during the early 20th century with little effect. In contrast, Hollander&rsquo;s injections of joints with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    acetate gave a much better response than the earlier substances, as well as proved that hydrocortisone acetate was the active antiinflammatory metabolite of cortisone [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/3\">",
"     3",
"    </a>",
"    ]. Hollander reported a series of more than 100,000 such injections of joints, bursa, and tendon sheaths in 4000 patients altogether by the early 1960s. The reported rate of iatrogenic infection from this series was less than 1 in 10,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18298068\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID INJECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Choice of glucocorticoid preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The questions of which glucocorticoid to inject and in which situation to do so were first addressed in 1954 when Hollander compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    acetate with tertiary-butyl acetate hydrocortisone and concluded that the latter had greater efficacy. Subsequent trials of different injectable glucocorticoids and clinical teaching permit the following conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      (Depo-Medrol) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide (Kenalog) cause less local postinjection flare than other long-acting agents.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       Triamcinolone",
"      </a>",
"      acetonide and triamcinolone hexacetonide (Aristospan) are less soluble and, therefore, longer-acting.",
"     </li>",
"     <li>",
"      Less soft tissue atrophy and less chance of tendon rupture are seen with dilution of the glucocorticoid by a local anesthetic. (See below.)",
"     </li>",
"     <li>",
"      Flocculation of the glucocorticoid (precipitation of steroid crystals out of solution into a presumably less bioavailable paste) occurs with addition of the methylparabens used as bacteriostatic agents in the local anesthetic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no large randomized, double-blind, prospective, controlled trials of various preparations with both toxicity and efficacy as end points. The single most revealing paper on this subject is a report of a 1993 survey of one-quarter of the American College of Rheumatology membership in the United States with a 62 percent response rate [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/5\">",
"     5",
"    </a>",
"    ]. This survey attempted to describe the practice pattern of rheumatologists with respect to three questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Which glucocorticoid should be used and at what dose?",
"     </li>",
"     <li>",
"      Should the glucocorticoid be mixed with local anesthetic?",
"     </li>",
"     <li>",
"      Should joint rest be prescribed after injection?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most striking finding in this survey was geographic variations of the type that have been used by policy analysts to detect health care utilization patterns without rational bases. The preferred injectable glucocorticoids were",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide (Kenalog) in the West,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    acetate (Depo-Medrol) in the East, and triamcinolone hexacetonide (Aristospan) in the Midwest. Even among these commonly employed preparations, the concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    equivalent varied at least twofold, but the usual dose for a knee injection was 1 mL regardless of concentration.",
"   </p>",
"   <p>",
"    Another finding was that the practice of combining glucocorticoid with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    anesthetic as a diluent had grown 40 percent since the mid-1970s. According to the 518 respondents to the survey, approximately 75 percent of rheumatologists trained after 1985 diluted the glucocorticoid injection with local anesthetic. Only 9 percent were aware of (or took seriously) the potential problem of bioavailability after flocculation of steroid crystals by exposure to parabens preservative in the lidocaine.",
"   </p>",
"   <p>",
"    These geographic and generational differences demonstrate that a good part of dogma on what and how much to inject rests only upon habit. The literature in this area will continue to be sparse if only for the reason that most techniques and agents work reasonably well; thus, the potential clinical advantages of testing one against another appear small, at least in terms of efficacy. In contrast, there might be significant gain from studies of toxicities of intraarticular and periarticular injection. However, such studies are difficult for the very same reason that injection remains a popular technique, occurring in one-sixth of all encounters between patients and rheumatologists. This reason is that adverse sequelae are rare, almost too rare to study.",
"   </p>",
"   <p>",
"    The limited prospect for more scientific data puts a premium on the knowledge of small series and anecdotal reports, particularly in the realm of toxicity (",
"    <a class=\"graphic graphic_table graphicRef74660 \" href=\"UTD.htm?14/25/14747\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide exclusively at standard doses of 40 mg (1 mL) for a large joint (knee, shoulder); 30 mg for medium-sized joints (wrist, ankle, elbow); and 10 mg for small spaces (metacarpophalangeal and proximal interphalangeal joints, tendon sheaths).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Should the glucocorticoid be mixed with a local anesthetic?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reasons to mix the glucocorticoid with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    have to do with the function of the local anesthetic as a diluent as well as its role as pain reliever. The rationales for mixing include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreasing the propensity of the glucocorticoid to cause atrophy",
"     </li>",
"     <li>",
"      Decreasing the tendency of the steroid crystals to serve as an irritant or proinflammatory factor (so-called postinjection flare) before the biochemical effect of the glucocorticoid takes over",
"     </li>",
"     <li>",
"      Use of the immediate relief from the anesthetic as evidence of good placement of the injection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these three rationales may be of critical importance in an individual patient. As an example, some partial rotator cuff atrophy, leading to a reduced volume of tissue in an area of impingement, is probably an important mechanism by which some long-lasting glenohumeral or subdeltoid bursa injections act. However, in some cases, excessive tendon atrophy may result in rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28564?source=see_link\">",
"     \"Joint aspiration or injection in adults: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postinjection flare is said to be most commonly associated with injection of crystals of glucocorticoid other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    . It occurs and resolves within 48 hours after injection, and it may be difficult to distinguish from iatrogenic infection. One helpful clue is that most iatrogenic joint infections seem to develop clinical signs a bit more slowly than a crystal-induced flare. In addition, postinjection flares primarily occur with soft tissue, tendon, or trigger point injections, while infections are rare and occur primarily with intraarticular injections.",
"   </p>",
"   <p>",
"    Finally, there is at least one blinded and randomized trial which suggests that shoulder injections directed at particular structures in the shoulder, depending upon physical examination findings, are more effective than a policy of routinely injecting anteriorly into the glenohumeral joint. This observation supports the practice of using a combined glucocorticoid and local anesthetic injection to judge the accuracy of the placement of the injection. If the local anesthetic relieves pain in the office but the glucocorticoid fails to work over the next 72 hours, then the disease is probably not amenable to injection therapy. The alternative hypothesis that the injection was not placed close enough to the disease is excluded by the favorable response to the local anesthetic.",
"   </p>",
"   <p>",
"    However, these observations in support of mixing the glucocorticoid preparation with local anesthetic must be balanced against two concerns: contamination of multidose vials and flocculation when the glucocorticoid is mixed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of an extra step of adding local anesthetic to the syringe may increase the risk of infection from multidose vials.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      without preservatives can be obtained in single dose vials; however, these more expensive preparations are not widely available.",
"     </li>",
"     <li>",
"      It is uncertain if the flocculation of steroid crystals caused by the parabens in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      reduces the efficacy of the injection. Precipitation of the glucocorticoid in mixture in the syringe can be seen within two minutes after the addition of the lidocaine solution. Some surgeons claim to have recovered paste-like flocculated glucocorticoid from operated carpal tunnels, suggesting that the flocculated steroid crystals may have a very long half-life when they are injected into a space without much synovial fluid. However, this degree of prolongation of action is not desirable.",
"     </li>",
"     <li>",
"      In addition, immediate relief of shoulder pain after injection is not necessarily attributable to good placement of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      . It may reflect needle placement itself via an uncertain mechanism. This could explain the occasional observation of immediate relief of pain from shoulder injection with glucocorticoid alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of definitive data, we tend to dilute the glucocorticoid preparation with an equal volume of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    for a specific indication. The acceptable alternative preferred by some experts is the routine use of combination with a local anesthetic for almost all injections, intra- and extraarticular. In the American College of Rheumatology membership survey, approximately two-thirds of rheumatologists in the United States generally diluted glucocorticoid injections with a local anesthetic.",
"   </p>",
"   <p>",
"    The two specific indications for dilution with local anesthetic are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of the analgesic response to verify effective needle placement within a complex anatomical site such as the shoulder",
"     </li>",
"     <li>",
"      Dilution of glucocorticoid to decrease atrophy in the supporting ligamentous structures of the small joints in the hand. The increase in volume caused by mixing with an equal volume of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      without epinephrine implies that most of the volume will infiltrate around the joint capsule in smaller joints (metacarpophalangeal and proximal interphalangeal joints) rather that enter the joint space.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Frequency of injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most authoritative sources suggest limiting intraarticular glucocorticoid injections in any given joint [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Safe rates of injection quoted range from four injections per lifetime of a joint with primary osteoarthritis (OA) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/8\">",
"     8",
"    </a>",
"    ] to one injection per month in joints severely affected by rheumatoid arthritis (RA) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. Some non-primate models, for example, have shown that repeated injections of glucocorticoid accelerate osteoarthritic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cartilage safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversy remains regarding the maximum safe frequency of intraarticular glucocorticoid for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repetitive intraarticular glucocorticoid injection is remarkably safe in short-term use compared with other treatments, carrying an infection rate possibly as low as 6 per 100,000 injections [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinical experience is contradictory. Some, but clearly not all, patients with RA can absorb as many as 10 injections per joint per year over a decade without any apparent glucocorticoid-induced cartilage loss [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/11\">",
"       11",
"      </a>",
"      ]. In addition, clinical reports have shown a low rate of accelerated osteoarthritic changes in joints treated with repetitive glucocorticoid injections [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies have demonstrated the capacity of glucocorticoids to inhibit the production of collagenases and other metalloproteases which may mediate cartilage destruction induced by RA or OA [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. In an equine model, glucocorticoid injections increase the production of joint surfactant by the synovial lining cells, thereby decreasing shear forces at the cartilage surface, improving regulation of cartilage hydration, and augmenting free radical scavenging [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data provide a theoretical mechanism for possible cartilage protection from inflammation by intraarticular glucocorticoid therapy. They also raise the question of whether the traditional limit of four injections per joint per year is too conservative for patients with RA.",
"   </p>",
"   <p>",
"    The most substantial patient-based research on repeated intraarticular glucocorticoid injections (average 10 injections per year) comes from a report in which 65 knees of patients with RA or primary OA were followed from 4 to 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/12\">",
"     12",
"    </a>",
"    ]. X-rays showed no deterioration in 15 knees, minimal or moderate deterioration in 38, marked deterioration in 10, and gross deterioration in two, both in the same patient. These observations were uncontrolled, making it impossible to determine if the radiologic deterioration in these two joints was attributable to the natural history of the underlying OA itself or to the cumulative effect of intensive glucocorticoid injection. Nevertheless, the findings demonstrate that this regimen does not predictably lead to joint destruction in most patients.",
"   </p>",
"   <p>",
"    In a well-designed trial in which 68 patients with OA were randomly assigned to receive intraarticular glucocorticoids or a sham injection of saline solution every three months for two years and which followed subjects clinically and radiographically, there were no significantly different effects upon cartilage thickness, a finding that suggests that repeated injections in patients with OA are neither chondrodestructive nor chondroprotective [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an attempt to address the relative benefit and risk of frequent injections in RA, we performed a study of bilateral pairs of large joints, excluding hand joints, in patients with longstanding RA who received four or more intraarticular injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide in a single year in one joint [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/6\">",
"     6",
"    </a>",
"    ]. The results seemed to show that the suppression of inflammation by intraarticular glucocorticoid injection may slow cartilage degradation from active RA.",
"   </p>",
"   <p>",
"    The most symptomatic joint (the intensely injected joint) lost cartilage at a rate equal to or lower than that of the contralateral joint. This trend was apparent in a subset of 13 patients with an average of 7.4 years of follow-up, which was then established as the cohort of a five-year prospective study. Joint replacement surgery was not significantly more common in the heavily injected joints after five years. The glucocorticoid regimen used in this study was the same as that described above (ie, 40 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide per injection in large joints); 1622 injections were performed in these 13 patients.",
"   </p>",
"   <p>",
"    These observations suggest that a strategy of frequent intraarticular glucocorticoid injection in established RA does not add a large increase in risk of joint replacement to the risk inherent in continued disease activity. It is even possible that frequent glucocorticoid injection offers some chondroprotection when the alternative is continuous disease activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Durability of clinical improvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some data on the duration of improvement in symptoms and signs of arthritis following intraarticular injection that suggest different results for inflammatory diseases, such as rheumatoid arthritis and juvenile idiopathic arthritis versus OA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early reports showed a several-month improvement in most patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    acetate injection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/4,17\">",
"     4,17",
"    </a>",
"    ]. McCarty reported that 88 percent of patients achieved relative remission in the small joints of hands and wrists lasting a mean of 22 months compared with contralateral control joints in the same patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/18\">",
"     18",
"    </a>",
"    ]. A regimen involving six weeks of splinting after injection of inflamed upper extremity joints allowed &ldquo;remission&rdquo; in three-quarters of inflamed joints injected one or two times per year [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeated injections may be particularly valuable in the treatment of pauciarticular onset juvenile idiopathic arthritis (juvenile rheumatoid arthritis). The use of joint injections in this disorder is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link&amp;anchor=H2046432#H2046432\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\", section on 'Intraarticular joint injection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis seems to be the disease with least durable response to intraarticular glucocorticoid injection, with most of the benefit compared with placebo dissipating within six weeks or less after the injection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/20-25\">",
"     20-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aspiration of inflammatory fluid prior to injection increases the durability of glucocorticoid injection response. In a study of 191 knee injections, aspiration of fluid prior to instillation of glucocorticoid cut the rate of relapse within six months in 50 to 23 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach is to inject very active large joints affected by RA as often as once per month for three months, with a limit of about four injections per year for any given joint. For joints affected by OA, we inject glucocorticoids as often as once every three months [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/26\">",
"     26",
"    </a>",
"    ], but only if no other therapy is effective. However, the overall duration of such therapy remains unclear, and a conservative approach is advisable. The case for frequent, palliative injection of OA becomes much stronger when the patient and the surgeon have already concluded that total joint arthroplasty is inevitable at some point in the future.",
"   </p>",
"   <p>",
"    Even when recognition of the inevitability of total joint replacement removes the prohibition against frequent injection of an osteoarthritic joint, it is difficult to increase the frequency of injection to greater than one injection per patient per four to six weeks. Systemic effects of glucocorticoids upon bone and skin usually supervene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HYALURONIC ACID DERIVATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Derivatives of hyaluronic acid are used in the treatment of patients with osteoarthritis (OA). The evidence describing the use of intraarticular hyaluronic acid derivatives and addressing their efficacy in OA are presented elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of experimental injectable agents or methods may enter the armamentarium for RA or OA in the future.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several disease-modifying antirheumatic drugs, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and tumor necrosis factor inhibitors, have been investigated as intraarticular agents for use in various forms of inflammatory arthritis, but they have mixed results [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/27-33\">",
"       27-33",
"      </a>",
"      ]. This approach is not in general use. (See appropriate topic reviews.)",
"     </li>",
"     <li>",
"      Intrasynovial gene therapy for disease-causing joint damage is being assessed. Particular interest has focused upon genes that lead to the local production of molecules that block the action of proinflammatory cytokines. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16746?source=see_link\">",
"       \"Cytokine networks in rheumatic diseases: Implications for therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Microspheres of gelatin and chondroitin, as well as liposomes, have been tested in experimental animals to control the release of protein drugs within the injected joint [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/34\">",
"       34",
"      </a>",
"      ]. As an example, complement receptor-1 linked to a membrane addressin successfully down-regulated inflammation in the adjuvant arthritis rat model [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30951/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281163763\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide for intraarticular and soft tissue injections at standard doses of 40 mg (1 mL) for a large joint, 30 mg for medium-sized joints, and 10 mg for small spaces, including interphalangeal joints and tendon sheaths. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Choice of glucocorticoid preparation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternative glucocorticoids for intraarticular injection include depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      hexacetonide. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Choice of glucocorticoid preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for which we dilute the glucocorticoid preparation with an equal volume of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      include the use of the analgesic response to verify effective needle placement within a complex anatomical site, such as the shoulder, and to decrease atrophy in the supporting ligamentous structures of the small joints in the hand. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Should the glucocorticoid be mixed with a local anesthetic?'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An acceptable, common, alternative approach is the routine dilution of glucocorticoids for injection with local anesthetic. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Should the glucocorticoid be mixed with a local anesthetic?'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The maximum safe frequency of intraarticular glucocorticoid is uncertain. Our approach is to inject very active large joints affected by rheumatoid arthritis as often as once per month for up to three months, with a limit of about four injections per year for any given joint. For joints affected by osteoarthritis, we inject glucocorticoids as often as once every three months, but only if no other therapy is effective. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Durability of clinical improvement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Rheumatoid arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Osteoarthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with plans for total joint replacement, we may increase the frequency of injection to a maximum of one joint injection every four to six weeks to limit the systemic effects of the glucocorticoids. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Derivatives of hyaluronic acid are used in the treatment of patients with osteoarthritis (OA). The evidence describing the use of intraarticular hyaluronic acid derivatives and addressing their efficacy in OA is presented elsewhere.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Pemberton R. Arthritis and rheumatoid conditions: Their nature and treatment, Lea and Febiger, Philadelphia 1935.",
"    </li>",
"    <li>",
"     Ropes MW, Bauer W. Synovial Fluid Changes in Joint Disease, The Commonwealth Fund, Harvard University Press, Cambridge 1953.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/3\">",
"      HOLLANDER JL, BROWN EM Jr, JESSAR RA, BROWN CY. Hydrocortisone and cortisone injected into arthritic joints; comparative effects of and use of hydrocortisone as a local antiarthritic agent. J Am Med Assoc 1951; 147:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/4\">",
"      HOLLANDER JL, JESSAR RA, BROWN EM Jr. Intra-synovial corticosteroid therapy: a decade of use. Bull Rheum Dis 1961; 11:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/5\">",
"      Centeno LM, Moore ME. Preferred intraarticular corticosteroids and associated practice: a survey of members of the American College of Rheumatology. Arthritis Care Res 1994; 7:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/6\">",
"      Roberts WN, Babcock EA, Breitbach SA, et al. Corticosteroid injection in rheumatoid arthritis does not increase rate of total joint arthroplasty. J Rheumatol 1996; 23:1001.",
"     </a>",
"    </li>",
"    <li>",
"     Owen DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th, Kelley WN, Harris Jr ED, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1993. p.545.",
"    </li>",
"    <li>",
"     Liang MH, Robb-Nicholson C, Roberts WN, Bannon L. Rheumatology: Problems in Primary Care, Medical Economics Books, New Jersey 1990. p.163.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/9\">",
"      BROWN EM Jr, FRAIN JB, UDELL L, HOLLANDER JL. Locally administered hydrocortisone in the rheumatic diseases; a summary of its use in 547 patients. Am J Med 1953; 15:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/10\">",
"      Behrens F, Shepard N, Mitchell N. Alterations of rabbit articular cartilage by intra-articular injections of glucocorticoids. J Bone Joint Surg Am 1975; 57:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/11\">",
"      Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 1981; 10:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/12\">",
"      Balch HW, Gibson JM, El-Ghobarey AF, et al. Repeated corticosteroid injections into knee joints. Rheumatol Rehabil 1977; 16:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/13\">",
"      Pelletier JP, Martel-Pelletier J, Cloutier JM, Woessner JF Jr. Proteoglycan-degrading acid metalloprotease activity in human osteoarthritic cartilage, and the effect of intraarticular steroid injections. Arthritis Rheum 1987; 30:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/14\">",
"      Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993; 36:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/15\">",
"      Hills BA, Ethell MT, Hodgson DR. Release of lubricating synovial surfactant by intra-articular steroid. Br J Rheumatol 1998; 37:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/16\">",
"      Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003; 48:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/17\">",
"      Hollander JL. Intrasynovial corticosteroid therapy in arthritis. Md State Med J 1970; 19:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/18\">",
"      McCarty DJ. Treatment of rheumatoid joint inflammation with triamcinolone hexacetonide. Arthritis Rheum 1972; 15:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/19\">",
"      McCarty DJ, Harman JG, Grassanovich JL, Qian C. Treatment of rheumatoid joint inflammation with intrasynovial triamcinolone hexacetonide. J Rheumatol 1995; 22:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/20\">",
"      MILLER JH, WHITE J, NORTON TH. The value of intra-articular injections in osteoarthritis of the knee. J Bone Joint Surg Br 1958; 40-B:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/21\">",
"      Dieppe PA, Sathapatayavongs B, Jones HE, et al. Intra-articular steroids in osteoarthritis. Rheumatol Rehabil 1980; 19:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/22\">",
"      Friedman DM, Moore ME. The efficacy of intraarticular steroids in osteoarthritis: a double-blind study. J Rheumatol 1980; 7:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/23\">",
"      Jones A, Doherty M. Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response. Ann Rheum Dis 1996; 55:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/24\">",
"      Gaffney K, Ledingham J, Perry JD. Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response. Ann Rheum Dis 1995; 54:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/25\">",
"      Raynauld JP. Clinical trials: impact of intraarticular steroid injections on the progression of knee osteoarthritis. Osteoarthritis Cartilage 1999; 7:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/26\">",
"      Intra-articular injections for osteoarthritis of the knee. Med Lett Drugs Ther 2006; 48:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/27\">",
"      Iagnocco A, Cerioni A, Coari G, et al. Intra-articular methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis: a clinical and sonographic study. Clin Rheumatol 2006; 25:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/28\">",
"      Hasso N, Maddison PJ, Breslin A. Intra-articular methotrexate in knee synovitis. Rheumatology (Oxford) 2004; 43:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/29\">",
"      Schatteman L, Gyselbrecht L, De Clercq L, Mielants H. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab. J Rheumatol 2006; 33:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/30\">",
"      Conti F, Ceccarelli F, Priori R, et al. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha. Ann Rheum Dis 2008; 67:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/31\">",
"      Bliddal H, Terslev L, Qvistgaard E, et al. Safety of intra-articular injection of etanercept in small-joint arthritis: an uncontrolled, pilot-study with independent imaging assessment. Joint Bone Spine 2006; 73:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/32\">",
"      Bliddal H, Terslev L, Qvistgaard E, et al. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol 2006; 35:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/33\">",
"      van der Bijl AE, Teng YK, van Oosterhout M, et al. Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial. Arthritis Rheum 2009; 61:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/34\">",
"      Brown KE, Leong K, Huang CH, et al. Gelatin/chondroitin 6-sulfate microspheres for the delivery of therapeutic proteins to the joint. Arthritis Rheum 1998; 41:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30951/abstract/35\">",
"      Linton SM, Williams AS, Dodd I, et al. Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum 2000; 43:2590.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7985 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30951=[""].join("\n");
var outline_f30_14_30951=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H281163763\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18298068\">",
"      GLUCOCORTICOID INJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Choice of glucocorticoid preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Should the glucocorticoid be mixed with a local anesthetic?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Frequency of injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cartilage safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Durability of clinical improvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HYALURONIC ACID DERIVATIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      INVESTIGATIONAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281163763\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7985\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7985|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/25/14747\" title=\"table 1\">",
"      Intraarticular steroid toxicity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16746?source=related_link\">",
"      Cytokine networks in rheumatic diseases: Implications for therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28564?source=related_link\">",
"      Joint aspiration or injection in adults: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28565?source=related_link\">",
"      Synovectomy for inflammatory arthritis of the knee",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_14_30952="Primidone: Drug information";
var content_f30_14_30952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Primidone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/5/15445?source=see_link\">",
"    see \"Primidone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/11/42167?source=see_link\">",
"    see \"Primidone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mysoline&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Primidone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F213361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous;",
"     </li>",
"     <li>",
"      Barbiturate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F213323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Seizure disorders",
"     </b>",
"     (grand mal, psychomotor, and focal): Oral: Days 1-3: 100-125 mg/day at bedtime; days 4-6: 100-125 twice daily; days 7-9: 100-125 mg 3 times daily; usual dose: 750-1500 mg/day in divided doses 3-4 times/day with maximum dosage of 2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients already receiving other anticonvulsants:",
"     </i>",
"     Initial: 100-125 mg at bedtime; gradually increase to maintenance dose as other drug is gradually decreased, continue until desired level obtained or other drug completely withdrawn. If goal is monotherapy, conversion should be completed over &ge;2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Essential tremor (unlabeled use):",
"     </b>",
"     Oral: Initial 12.5-25 mg/day at bedtime; titrate up to 250 mg/day in 1-2 divided doses; doses up to 750 mg/day may be beneficial",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F213340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/11/42167?source=see_link\">",
"      see \"Primidone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Seizure disorders (grand mal, psychomotor, and focal):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children &lt;8 years:",
"     </i>",
"     Initial: Days 1-3: 50 mg/day given at bedtime; days 4-6: 50 mg twice daily; days 7-9: 100 mg twice daily; usual dose: 375-750 mg/day in 3-4 divided doses (10-25 mg/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children &ge;8 years:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F213324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F213325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults (Aronoff, 2007):",
"     <b>",
"      Note:",
"     </b>",
"     Avoid in renal failure if possible; due to active metabolites with long half-lives and complex kinetics:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: Administer every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Administer dose postdialysis",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F213326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased side effects may occur in severe liver disease. Monitor plasma levels and adjust dose accordingly.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mysoline&reg;: 50 mg, 250 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10134268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Apo-Primidone&reg;: 125 mg, 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10523384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM222370.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM222370.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F213295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of grand mal, psychomotor, and focal seizures",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F213358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Benign familial tremor (essential tremor)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F213368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Primidone may be confused with predniSONE, primaquine, pyridoxine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F213359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, drowsiness, emotional disturbances, fatigue, hyperirritability, suicidal ideation, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Morbilliform skin eruptions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, granulocytopenia, megaloblastic anemia (idiosyncratic), red cell aplasia/hypoplasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia, nystagmus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F213298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenobarbital; porphyria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F213280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression or suicidal tendencies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoadrenalism: Use with caution in patients with hypoadrenalism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Substance abuse: Use with caution in patients with a history of drug abuse; potential for drug dependency exists. Tolerance or psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in patients who are debilitated; may cause paradoxical responses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may cause paradoxical responses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children; may cause paradoxical responses. Primidone's metabolite, phenobarbital, has been associated with cognitive deficits in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute pain: Do not administer to patients in acute pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F213356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (strong), CYP2B6 (strong), CYP2C8 (strong), CYP2C9 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Primidone may enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: Primidone may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: Primidone may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Primidone may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosyntropin: May enhance the hepatotoxic effect of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inducers (Strong) may increase the metabolism of CYP1A2 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Dexmethylphenidate may increase the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Primidone. Primidone may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Primidone may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations may increase. Primidone may decrease the serum concentration of Felbamate. Management: In patients receiving primidone, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily and reduce primidone dose by 20%. Monitor for increased phenobarbital concentrations/effects and decreased felbamate concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Folic Acid: May decrease the serum concentration of Primidone. Additionally, folic acid may decrease concentrations of active metabolites of primidone (e.g., phenobarbital).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Primidone may decrease the serum concentration of LamoTRIgine.  Management: Adjust dose per lamotrigine prescribing information guidelines during primidone treatment.  Monitor for decreased concentration/effect if primidone is initiated/dose increased or increased concentration/effect if primidone is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May decrease the serum concentration of Primidone. Additionally, leucovorin/levoleucovorin may decrease concentrations of active metabolites of primidone (e.g., phenobarbital).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levomefolate: May decrease serum concentrations of the active metabolite(s) of Primidone. Levomefolate may decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Methylphenidate may increase the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Primidone may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Primidone may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: Primidone may decrease the serum concentration of Rufinamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Primidone. More specifically, the metabolism of phenobarbital, primidone's primary active metabolite, would be decreased. Primidone may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F213313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Protein-deficient diets increase duration of action of primidone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F213301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Primidone and its metabolites (PEMA, phenobarbital, and p-hydroxyphenobarbital) cross the placenta; neonatal serum concentrations at birth are similar to those in the mother. Withdrawal symptoms may occur in the neonate and may be delayed due to the long half-life of primidone and its metabolites. Use may be associated with birth defects and adverse events; the use of folic acid throughout pregnancy and vitamin K during the last month of pregnancy is recommended. Epilepsy itself, number of medications, genetic factors, or a combination of these probably influence the teratogenicity of anticonvulsant therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to primidone during pregnancy are encouraged to enroll themselves into the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F213329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP recommends use &ldquo;with caution&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F213302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Primidone and its metabolites (PEMA, phenobarbital, and p-hydroxyphenobarbital) are found in breast milk (variable concentrations). The manufacturer recommends discontinuing breast-feeding if undue drowsiness and somnolence occur in the newborn.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F213303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Folic acid: Low erythrocyte and CSF folate concentrations. Megaloblastic anemia has been reported. To avoid folic acid deficiency and megaloblastic anemia, some clinicians recommend giving patients on anticonvulsants prophylactic doses of folic acid and cyanocobalamin.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F213300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mysoline Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $270.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $977.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Primidone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $49.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $99.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F213289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum primidone and phenobarbital concentration, neurological status. Due to CNS effects, monitor closely when initiating drug in elderly. Monitor CBC and sequential multiple analysis-12 (SMA-12) at 6-month intervals to compare with baseline obtained at start of therapy. Monitor for suicidality (eg, suicidal thoughts, depression, behavioral changes). Since elderly metabolize phenobarbital at a slower rate than younger adults, it is suggested to measure both primidone and phenobarbital levels together.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F213292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: Children &lt;5 years: 7-10 mcg/mL (SI: 32-46 micromole/L); Adults: 5-12 mcg/mL (SI: 23-55 micromole/L); toxic effects rarely present with levels &lt;10 mcg/mL (SI: 46 micromole/L) if phenobarbital concentrations are low. Dosage of primidone is adjusted with reference mostly to the phenobarbital level; Toxic: &gt;15 mcg/mL (SI: &gt;69 micromole/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Primidone (NZ);",
"     </li>",
"     <li>",
"      Cyral (AT);",
"     </li>",
"     <li>",
"      Liskantin (BG, CZ, DE, EE, LU);",
"     </li>",
"     <li>",
"      Majsolin (HR);",
"     </li>",
"     <li>",
"      Mizodin (PL);",
"     </li>",
"     <li>",
"      Mutigan (VE);",
"     </li>",
"     <li>",
"      Mylepsinum (DE);",
"     </li>",
"     <li>",
"      Mysoline (AE, AR, AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CN, CY, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, IE, IN, IQ, IR, IT, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, OM, PT, PY, QA, RU, SA, SC, SD, SE, SK, SL, SN, SY, TN, TR, TW, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Primidon (HR);",
"     </li>",
"     <li>",
"      Prysoline (IL);",
"     </li>",
"     <li>",
"      Sertan (HN, HU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F213279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases neuron excitability, raises seizure threshold similar to phenobarbital; primidone has two active metabolites, phenobarbital and phenylethylmalonamide (PEMA); PEMA may enhance the activity of phenobarbital",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F213297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 60% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Adults: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to phenobarbital (active)  by oxidation and to phenylethylmalonamide (PEMA; active) by scission of the heterocyclic ring",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (age dependent): Primidone: Mean: 5-15 hours (variable); PEMA: 16 hours (variable)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~3 hours (variable)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (40% as unchanged drug; the remainder is unconjugated PEMA, phenobarbital and its metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30952/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 91.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chen JJ and Swope DM, &ldquo;Essential Tremor: Diagnosis and Treatment,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(9):1105-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30952/abstract-text/14524643/pubmed\" id=\"14524643\" target=\"_blank\">",
"        14524643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Louis ED, &ldquo;Clinical Practice. Essential Tremor,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(12):887-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30952/abstract-text/11565522/pubmed\" id=\"11565522\" target=\"_blank\">",
"        11565522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McNamara JO, &ldquo;Drugs Effective in the Therapy of the Epilepsies,&rdquo; Gardman JG, Limbird LE, eds,",
"      <i>",
"       Goodman and Gilman's The Pharmacological Basis of Therapeutics",
"      </i>",
"      , 10th ed, New York, NY: McGraw-Hill, 2001:532.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nau H, Rating D, H&auml;user I, et al, \"Placental Transfer and Pharmacokinetics of Primidone and Its Metabolites Phenobarbital, PEMA and Hydroxyphenobarbital in Neonates and Infants of Epileptic Mothers,\"",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1980, 18(1):31-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30952/abstract-text/7398746/pubmed\" id=\"7398746\" target=\"_blank\">",
"        7398746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pahwa R and Lyons KE, &ldquo;Essential Tremor: Differential Diagnosis and Current Therapy,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 2003, 115(2):134-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30952/abstract-text/12893400/pubmed\" id=\"12893400\" target=\"_blank\">",
"        12893400",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Porter RJ, Meldrum BD, &ldquo;Antiepileptic Drugs,&rdquo; Katzung BG, ed,",
"      <i>",
"       Basic &amp; Clinical Pharmacology",
"      </i>",
"      , 6th ed, East Norwalk, CT: Appleton &amp; Lange, 1995:369.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwankhaus JD, Kattah JC, Lux WE, et al, &ldquo;Primidone/Phenobarbital-Induced Periodic Alternating Nystagmus,&rdquo;",
"      <i>",
"       Ann Ophthalmol",
"      </i>",
"      , 1989, 21(6):230-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/14/30952/abstract-text/2764437/pubmed\" id=\"2764437\" target=\"_blank\">",
"        2764437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9811 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30952=[""].join("\n");
var outline_f30_14_30952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213318\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213319\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213361\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213323\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213340\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213324\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213325\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213326\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213291\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10134268\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213276\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10523384\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213295\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213358\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213368\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213359\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213298\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213280\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213356\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213285\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213313\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213301\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213329\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213302\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213303\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213300\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213289\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213292\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038778\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213279\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213297\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9811\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9811|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/5/15445?source=related_link\">",
"      Primidone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/11/42167?source=related_link\">",
"      Primidone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_14_30953="Etiology and pathogenesis of neonatal encephalopathy";
var content_f30_14_30953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and pathogenesis of neonatal encephalopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/14/30953/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30953/contributors\">",
"     Sidhartha Tan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30953/contributors\">",
"     Yvonne Wu, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/14/30953/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30953/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30953/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/14/30953/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30953/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/14/30953/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal encephalopathy is a heterogeneous syndrome characterized by signs of central nervous system dysfunction in newborn infants. Clinical suspicion of neonatal encephalopathy should be considered in any infant exhibiting an abnormal level of consciousness, seizures, tone and reflex abnormalities, apnea, aspiration, feeding difficulties [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], and an abnormal hearing screen.",
"   </p>",
"   <p>",
"    This topic will review the etiology and pathogenesis of neonatal encephalopathy. Other clinical aspects of this syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Neonatal encephalopathy\" has emerged as the preferred term to describe central nervous system dysfunction in the newborn period [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The terminology does not imply a specific underlying pathophysiology, which is appropriate since the nature of brain injury causing neurologic impairment in a newborn is poorly understood. While neonatal encephalopathy was once automatically ascribed to hypoxia-ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/4\">",
"     4",
"    </a>",
"    ], it is now known that hypoxia-ischemia is only one of many possible contributors to neonatal encephalopathy. Whether a particular newborn's encephalopathy can be attributed to hypoxic-ischemic brain injury is often unclear.",
"   </p>",
"   <p>",
"    Some investigators require stringent criteria for using the term neonatal encephalopathy, such as two or more symptoms of encephalopathy lasting over 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/5\">",
"     5",
"    </a>",
"    ], while others require no more than a low five minute Apgar score [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the use of Apgar scores alone is problematic, as Apgar scores may be low due to maternal analgesia or prematurity, or can be normal in the presence of acute hypoxia-ischemic injury.",
"   </p>",
"   <p>",
"    Neonatal encephalopathy usually refers to central nervous system dysfunction in term and near term infants, but for the purposes of this review, encephalopathy of the preterm infant has also been included.",
"   </p>",
"   <p>",
"    When neonatal encephalopathy is indisputably due to hypoxic-ischemic (anoxic) brain injury, it is appropriate to use the term hypoxic-ischemic encephalopathy (HIE) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/7\">",
"     7",
"    </a>",
"    ]. Since the precise cause and temporal onset of neonatal encephalopathy is unknown in most cases, some experts advocate calling the condition &ldquo;presumed HIE&rdquo; or &ldquo;apparent HIE&rdquo; when the clinical features and neonatal brain injury patterns on MRI suggest that HIE is the most likely mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/8\">",
"     8",
"    </a>",
"    ]. Others favor using the non-specific term &ldquo;neonatal encephalopathy&rdquo; whenever there is doubt as to the underlying mechanism of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/3\">",
"     3",
"    </a>",
"    ]. It remains to be established whether neuroimaging or other testing can one day be used as a gold standard for determining when prenatal hypoxia, birth asphyxia, or hypoxic-ischemic brain injury is responsible for neonatal encephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is an increased risk of cerebral palsy associated with neonatal encephalopathy. However, not all cases of cerebral palsy or later developmental deficits have prior neonatal encephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=see_link\">",
"     \"Epidemiology and etiology of cerebral palsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"     \"Clinical features of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Timing of insult",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common crucial problem is the inability to time the onset, duration, magnitude, and the single or repetitive nature of the exact insult that causes brain injury resulting in neonatal encephalopathy. This is an important point to consider in view of emerging neuroprotective therapies such as hypothermia. The uncertain timing and etiology of brain injury in most cases of neonatal encephalopathy also fuels birth injury malpractice litigation. Malpractice cases, and too often clinicians, typically focus on events around the time of delivery, which happens to be the time (hours) when the majority of data from pregnant women are obtained, whereas the rest of pregnancy is relatively unmonitored [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/4\">",
"     4",
"    </a>",
"    ]. However, it is usually unknown whether the ultimate brain injury is caused by the events only around delivery or by cumulative insults throughout pregnancy.",
"   </p>",
"   <p>",
"    The definition of asphyxia is \"&hellip;a condition of impaired blood gas exchange leading, if it persists, to progressive hypoxemia and hypercapnia. Diagnosis requires a blood gas&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/9\">",
"     9",
"    </a>",
"    ]. However, even with state-of-art monitoring, there is presently no reliable measure of brain function, brain oxygenation, or cerebral blood flow during the prenatal period or even in the intrapartum period. Therefore, the terms \"birth asphyxia\" and \"fetal distress\" are not always used appropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from studies of neonatal encephalopathy using brain MRI, near-infrared spectroscopy and electroencephalogram monitoring suggest that the immediate perinatal period is important for evolution of brain injury in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/11\">",
"     11",
"    </a>",
"    ]. One report evaluated 351 term infants with either neonatal encephalopathy (defined as the presence of abnormal tone, feeding difficulties, altered alertness, and at least three of several criteria suggesting possible perinatal hypoxic-ischemia) or seizures alone during the first three days of life [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/12\">",
"     12",
"    </a>",
"    ]. Brain MRI was performed in the first one to two weeks after birth.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the group with encephalopathy, lesions suggestive of acute brain injury were found in 80 percent; most of the lesions were bilateral abnormalities in basal ganglia, thalami, cortex, or white matter, although focal infarction was detected in eight infants.",
"     </li>",
"     <li>",
"      In the group with only neonatal seizures, acute ischemic or hemorrhagic strokes were found in 69 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical signs that point to an early antenatal onset of neonatal encephalopathy include intrauterine growth restriction, small head size (if both head and body size are small then the insult could be in the first two trimesters of pregnancy), contractures, and features suggestive of arthrogryposis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Obstetricians and Gynecologists (ACOG), in collaboration with the American Academy of Pediatrics, convened a task force on neonatal encephalopathy and cerebral palsy. According to ACOG task force, four essential criteria (",
"    <a class=\"graphic graphic_table graphicRef66304 \" href=\"UTD.htm?6/27/6587\">",
"     table 1",
"    </a>",
"    ) are required to define an intrapartum asphyxial event sufficient to cause cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/13\">",
"     13",
"    </a>",
"    ]. However, only one criterion &mdash; metabolic acidosis on umbilical cord arterial blood at birth &mdash; is helpful to the clinician in the immediate postnatal period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and etiology of cerebral palsy\", section on 'Perinatal asphyxia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More importantly, for timing of the peripartum events that may be related to development of cerebral palsy, ACOG suggests the following criteria (",
"    <a class=\"graphic graphic_table graphicRef67282 \" href=\"UTD.htm?10/10/10411\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of a signal event immediately before or during labor",
"     </li>",
"     <li>",
"      Sudden onset of fetal bradycardia patterns",
"     </li>",
"     <li>",
"      Apgar score of 0 to 3 after five minutes",
"     </li>",
"     <li>",
"      Onset of a multisystem disorder in the first 72 hours",
"     </li>",
"     <li>",
"      Early brain imaging showing acute nonfocal cerebral abnormality",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a presumption that the absence of metabolic acidosis rules out hypoxia-ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/14\">",
"     14",
"    </a>",
"    ] but this may not necessarily be true for early antepartum episodes of hypoxia-ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although few studies have adequately evaluated risk factors for neonatal encephalopathy other than hypoxia-ischemia, a variety of prenatal and obstetric predictors have been identified from the available data. In a large population-based cohort of cases of neonatal encephalopathy from Western Australia, 69 percent had only antepartum risk factors, 25 percent had both antepartum and intrapartum risk factors, 4 percent had evidence of only intrapartum hypoxia, and 2 percent had no identified risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, approximately 70 percent of neonatal encephalopathy cases were associated with events arising before the onset of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/13\">",
"     13",
"    </a>",
"    ]. Similarly, in a registry of over 4100 infants with neonatal encephalopathy, 46 percent had fetal risk factors and 27 percent had maternal risk factors predating the onset of labor, while only 15 percent had a clinically recognized sentinel event capable of causing asphyxia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antepartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of neonatal encephalopathy cases have their antecedents in the prenatal period. It is unknown whether neonatal encephalopathy occurs as a result of a single insult (such as hypoxia-ischemia), multiple insults (infection with prematurity with hypoxia-ischemia), or combinations of acute or chronic conditions.",
"   </p>",
"   <p>",
"    The highest quality population-based study that evaluated risk factors for neonatal encephalopathy compared 164 infants with neonatal encephalopathy and 400 randomly selected controls from term infants born in Western Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/5\">",
"     5",
"    </a>",
"    ]. The study identified a number of antepartum risk factors, which are grouped under categories based on the maternal-placental-fetal unit (",
"    <a class=\"graphic graphic_figure graphicRef70341 \" href=\"UTD.htm?18/53/19295\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Preconceptual factors including maternal unemployment, family history of seizures or neurologic disorder, and infertility treatment",
"     </li>",
"     <li>",
"      Maternal thyroid disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placental",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe preeclampsia",
"     </li>",
"     <li>",
"      Post-dates",
"     </li>",
"     <li>",
"      Abnormal appearance of the placenta",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intrauterine growth restriction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among these antepartum risk factors, intrauterine growth restriction (IUGR) was the strongest (relative risk [RR] 38.2, 95% CI 9.4-154.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/5\">",
"     5",
"    </a>",
"    ]. Although most babies with neonatal encephalopathy do not meet the criteria of IUGR, a small hospital-based case-control study found that a greater proportion of infants with neonatal encephalopathy were below the 10th percentile of growth potential compared with controls, and the difference was statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/17\">",
"     17",
"    </a>",
"    ]. These studies suggest that there are antenatal factors contributing to the brain injury. Unfortunately, IUGR provides no clue to the etiology (",
"    <a class=\"graphic graphic_figure graphicRef60212 \" href=\"UTD.htm?27/38/28271\">",
"     figure 2",
"    </a>",
"    ) because both external maternal and placental factors can affect fetal growth in addition to intrinsic factors.",
"   </p>",
"   <p>",
"    Placental thrombosis, infection, and disturbed uteroplacental flow have also been associated with neonatal encephalopathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a hospital-based case-control study comparing 93 cases of neonatal encephalopathy to 387 controls, placental findings of fetal thrombotic vasculopathy, funisitis, and accelerated villous maturation were independently associated with neonatal encephalopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study found that the frequency of severe placental lesions was fivefold higher among 83 cases of neonatal encephalopathy from a medicolegal registry than among 250 controls (52 to 10 percent). These lesions included fetal thrombotic vasculopathy, chronic villitis with obliterative fetal vasculopathy, chorioamnionitis with severe fetal vasculitis, and meconium-associated fetal vascular necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of 100 term newborns who received hypothermia therapy for neonatal encephalopathy, placental abnormalities were more common among newborns (n = 49) who did not have a sentinel event (ie, a clinical history of disruption of blood flow to the fetus during delivery) such as placental abruption, uterine rupture, tight nuchal cord or cord prolapse [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/20\">",
"       20",
"      </a>",
"      ]. As an example, an inflammatory pathology was significantly more frequent in infants without sentinel events (43 percent, versus 14 percent for infants with sentinel events).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of the placental lesions result in some form of hypoxic-ischemic damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intrapartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Western Australia population-based study cited above, intrapartum risk factors for neonatal encephalopathy were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent occipitoposterior position",
"     </li>",
"     <li>",
"      Maternal fever",
"     </li>",
"     <li>",
"      Emergency cesarean delivery",
"     </li>",
"     <li>",
"      Operative vaginal delivery",
"     </li>",
"     <li>",
"      Acute intrapartum events",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An acute intrapartum event, such as a placental abruption or uterine rupture, conferred a fourfold increased risk of neonatal encephalopathy, but was present in only 8 percent of infants with neonatal encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/15\">",
"     15",
"    </a>",
"    ]. In the series of 158 medicolegal cerebral palsy cases, sentinel intrapartum events were present in 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of maternal fever as a risk factor for neonatal encephalopathy is illustrated by the following reports [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based report that compared 1060 newborn cases of neonatal encephalopathy with 5330 unaffected control newborns, independent risk factors for neonatal encephalopathy were isolated intrapartum maternal fever (RR 3.1, 95% CI 2.3-4.2) and chorioamnionitis (RR 5.4, 95% CI 3.6-7.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort study that identified 25 cases of moderate to severe neonatal encephalopathy from 8299 term births, maternal fever had a sixfold increased risk of neonatal encephalopathy compared to a 12-fold increase for acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/24\">",
"       24",
"      </a>",
"      ]. Although there was a multiplicative increased risk with acidosis (76-fold), the effect of maternal fever seemed to have no statistical interaction with acidosis, implying that maternal fever and acidosis represent different causal pathways.",
"     </li>",
"     <li>",
"      In a prospective study of infants exposed to maternal chorioamnionitis, there was a threefold increase in neonatal depression and neonatal intensive care unit admission for newborns with elevated temperature [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have found that maternal fever, often accompanied by a diagnosis of chorioamnionitis, is associated with low Apgar scores, neonatal seizures, and a diagnosis of \"birth asphyxia\" among infants who develop cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An interaction between brain injury due to inflammation and hypoxia-ischemia has been suggested by the finding in a case-control study of an association between maternal chorioamnionitis and cerebral palsy in children with evidence of hypoxic-ischemic brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/28\">",
"     28",
"    </a>",
"    ], and by the observation of increased cytokines in the cerebrospinal fluid of patients with neonatal encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for resuscitation in the delivery room is itself a poor prognostic sign as it is associated with an increased risk at eight years of age of having a lower (&lt;80) IQ score, even if the infant does not exhibit encephalopathy in the newborn period (odds ratio 1.65, 95% CI 1.13-2.43) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HYPOXIC-ISCHEMIC INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted earlier, it is appropriate to use the term hypoxic-ischemic encephalopathy (HIE) when neonatal encephalopathy is due to hypoxic-ischemic brain injury. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Terminology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The signs and symptoms of HIE, as well as outcome, depend upon several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The immediate nervous system injury sustained during the hypoxic-ischemic insult",
"     </li>",
"     <li>",
"      Physiologic properties that lead to selective vulnerabilities of certain cell populations",
"     </li>",
"     <li>",
"      The presence of endogenous protective mechanisms",
"     </li>",
"     <li>",
"      Consequences of hypoxia-ischemia that lead to secondary injuries (eg, reperfusion injury, edema, increased intracranial pressure, abnormalities of autoregulation, and hemorrhage)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypoxia can result from ischemia (ie, a lack of sufficient blood flow to all or part of an organ), insufficient inspired oxygen, or inadequate blood oxygen-carrying capacity (eg, inadequate oxygen in inspired air, severe anemia, carbon monoxide poisoning). Regardless of the cause, cardiac and vascular compromise ultimately occur when hypoxia is prolonged. The result is hypotension, ischemia, and anaerobic metabolism leading to lactic acidosis. Thus, ischemia is both a cause and a result of hypoxia and compounds the complications of hypoxia by impairing the removal of metabolic and respiratory by-products (eg, lactic acid, carbon dioxide).",
"   </p>",
"   <p>",
"    Fetal hypoxic-ischemic brain injury and subsequent HIE can occur by one or more of the following mechanisms (",
"    <a class=\"graphic graphic_table graphicRef67794 \" href=\"UTD.htm?36/17/37147\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal, via impaired oxygenation (eg, asthma, pulmonary embolism, pneumonia) or inadequate perfusion of maternal placenta (eg, cardiorespiratory arrest, maternal hypotension, preeclampsia, chronic vascular disease)",
"     </li>",
"     <li>",
"      Placental, via abruptio placenta, tight nuchal cord, cord prolapsed, true knot, or uterine rupture (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21929?source=see_link\">",
"       \"Placental pathology in cases of neurologically impaired infants\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fetal, via impaired fetal",
"      <span class=\"nowrap\">",
"       oxygenation/perfusion",
"      </span>",
"      (eg, fetomaternal hemorrhage, fetal thrombosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antecedent events and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain injury from HIE frequently occurs before the onset of labor. Supporting evidence comes from a neuropathologic study of 70 infants who died within seven days of birth [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/31\">",
"     31",
"    </a>",
"    ]. Using criteria of low five minute Apgar score and umbilical cord or initial blood gas pH &lt;7.1 for asphyxia, findings consistent with brain damage before the onset of labor were present in all asphyxiated and encephalopathic infants. In addition, the same findings were present in 38 percent of term infants, 52 percent of preterm infants, and 1 of 12 infants without any evidence of birth asphyxia.",
"   </p>",
"   <p>",
"    This report reveals that some cases of HIE die before manifesting brain injury or clinical signs of neonatal encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, brain injury associated with HIE may be present without clinical signs of neonatal encephalopathy. However, there are limitations to extrapolating findings from autopsy studies in that the nature of death, failed resuscitation, and terminal drugs are not controlled for in most instances.",
"   </p>",
"   <p>",
"    A major risk factor for HIE is that of multiple gestations, particularly the presence of monochorionic twins. A study of preterm infants of multiple gestations found that the incidence of antenatal white matter necrosis on cranial ultrasound was significantly higher in monochorionic than in dichorionic infants (30 vs 3.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In preterm infants meeting criteria for HIE, placental abruption is more likely to be identified as the antecedent event [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/33\">",
"     33",
"    </a>",
"    ] than uterine rupture and cord prolapse, which are more common sentinel events among term infants diagnosed with HIE [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/34\">",
"     34",
"    </a>",
"    ]. In preterm infants, HIE is associated with injury on 36 week MRI scan involving the basal ganglia (mostly severe), white matter (mostly mild), brainstem, and cortex in 75, 89, 44 and 58 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies emphasize the importance of early brain imaging in documenting, and possibly timing, brain lesions, as well as the importance of postmortem examinations in cases of stillbirth and neonatal deaths. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Level and duration of hypoxia-ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of hypoxia-ischemia that causes neonatal encephalopathy is unknown, but animal studies provide some information. There are two experimental paradigms that present with different pathophysiological pathways: umbilical cord occlusion and acute placental insufficiency.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occlusion of the umbilical cord results in cardiovascular compromise because of the removal of a low resistive vascular bed",
"     </li>",
"     <li>",
"      In sheep, fetuses can survive up to 30 minutes of occlusion with increasing brain damage observed in term sheep compared to premature sheep fetuses [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/35\">",
"       35",
"      </a>",
"      ], while 20 minute occlusion may not cause any brain injury [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In non-human primates, it was long believed that permanent neurologic injury occurred with occlusion of 12 to 17 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical corollary of umbilical cord prolapse has a more varied response, probably because of the presence of some blood flow in the prolapsed cord. In humans, umbilical cord prolapse is an obstetric emergency except for the extreme premature gestation mother. In a chart review of 87 cases of cord prolapse among 36,500 deliveries, the median time from discovery to delivery was 15 minutes, with the longest being 14 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/39\">",
"     39",
"    </a>",
"    ]. There was no relation between time of discovery to delivery and postnatal mortality or morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/39\">",
"     39",
"    </a>",
"    ]. The longest tolerated time of umbilical cord prolapse without major consequences &mdash; three days &mdash; was observed in an extremely premature infant [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/40\">",
"     40",
"    </a>",
"    ], suggesting that the duration becomes critical only near term.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute placental insufficiency results in fetal compromise due to impaired ability to exchange gas and nutrients.",
"     </li>",
"     <li>",
"      A study of acute placental insufficiency (via uterine ischemia) in rabbits at 70 percent gestation found that animals subjected to 30 minutes of global hypoxia-ischemia were no different than controls [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/41\">",
"       41",
"      </a>",
"      ]. However, 40 minutes of global hypoxia-ischemia increased fetal mortality from 0 to 25 percent, and increased marked motor deficits at birth in the survivors from 0 to 75 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When experimental global hypoxia-ischemia is mild and chronic, it results in intrauterine growth restriction but may or may not result in brain injury [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, the onset of acute placental insufficiency states such as placental abruption in humans is almost always unknown. The ultimate example of acute placental insufficiency is uterine rupture in clinical situations. In one retrospective series of 21 cases of term infants with symptomatic uterine rupture, one third manifested HIE [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The spectrum of HIE injury and outcome can be summarized as in the Figure (",
"    <a class=\"graphic graphic_figure graphicRef53458 \" href=\"UTD.htm?40/7/41072\">",
"     figure 3",
"    </a>",
"    ). The intensity of the insult can be modified by prior events that may serve as a preconditioning stimulus. Also, there is a complex interaction of infection with hypoxia-ischemia. As an example, preeclampsia may be a protective factor for infants born to mothers with chorioamnionitis and at risk for cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vulnerable regions of developing brain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxia-ischemia may have deleterious effects on vulnerable cell populations peculiar to the developmental stage (",
"    <a class=\"graphic graphic_figure graphicRef54449 \" href=\"UTD.htm?17/55/18303\">",
"     figure 4",
"    </a>",
"    ), causing discrete injuries that could also affect seizure threshold or cognition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late oligodendroglial progenitors are vulnerable to injury in early prematurity with resulting predominant white matter injury in premature infants [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the term neonate with ischemic brain injury, however, certain neurons in the deep gray nuclei and perirolandic cortex are most likely to be affected. Acute cell injury can trigger continuing loss of cells. There are neural-glial cell interactions that can increase the brain injury. Selective damage to neurons in the subcortical gray matter can directly contribute to long-term apoptosis in distal neuronal structures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both gray and white matter injury occur in preterm and term neonates with HIE. Early detection of recent hypoxic-ischemic insults depends upon apparent diffusion coefficient (ADC) measurements on MRI. Beyond a week after the onset of the insult, evidence of gray matter injury by neuroimaging is scant unless there is a significant decrease in volume of gray matter regions or an increase in ventricular size or obvious infarcts and hemorrhage. White matter injury is somewhat easier to detect by diffusion tensor imaging (DTI), as the fractional anisotropy of white matter bundles normally increase with age, leading to an ability to detect minor decreases in fractional anisotropy in WM regions. However, while DTI is performed at some tertiary centers, it is not yet widely available in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mechanisms of neuronal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxia-ischemia initially causes energy failure and loss of mitochondrial function. This is accompanied by membrane depolarization, brain edema, an increase of neurotransmitter release and inhibition of uptake, and an increase of intracellular calcium that sets off additional pathologic cascades [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/47\">",
"     47",
"    </a>",
"    ]. These include oxidative stress, with the production of reactive oxygen species and interaction with nitric oxide pathway to produce reactive nitrogen species [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It was once believed that reactive species caused damage only if antioxidant defenses were overwhelmed, thus upsetting the balance between oxidants and antioxidants. However, it is now realized that the interaction itself between reactive species and antioxidant defenses ultimately causes cellular injury and death (ie, the yin-yang theory of both being necessary) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/49\">",
"     49",
"    </a>",
"    ]. Reperfusion exacerbates the oxidative stress with a burst of reactive oxygen species.",
"   </p>",
"   <p>",
"    The response of the fetus to the hypoxic-ischemic insult determines the subsequent injurious cascades and the clinical manifestations that result. One study monitored the response of rabbit fetus brains in utero to global hypoxia using MRI diffusion-weighted sequences and apparent diffusion coefficient (ADC) mapping as a marker of ischemic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/50\">",
"     50",
"    </a>",
"    ]. Fetuses that showed a precipitous drop in brain ADC at the end of 40 minutes of global hypoxia manifested hypertonia and postural changes after birth, while those without a drop in ADC were relatively normal at birth. Thus, after the hypoxic-ischemic insult, the initial energy failure and oxidative stress probably play a critical role in subsequent cascades (",
"    <a class=\"graphic graphic_figure graphicRef62126 \" href=\"UTD.htm?10/62/11232\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Excitotoxic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excitotoxic cellular injury occurs via excess activation of glutamate receptors, which leads to several forms of cell death. There are four receptor types for glutamate [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/52\">",
"     52",
"    </a>",
"    ], which are the N-methyl-d-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA), kainate, and metabotropic glutamate receptors. The metabotropic receptors are not directly coupled to ion channels.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The NMDA receptors are the most avid and physiologically active. The channels activated by NMDA receptors are voltage-dependent and calcium-permeable. Their activation causes neuron depolarization [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/53\">",
"       53",
"      </a>",
"      ]. Repeated depolarization of a neuron by unregulated glutamate release results in accumulation of intracellular calcium. During hypoxia-ischemia, there is failure to rapidly pump synaptically released glutamate back across the cell membrane, resulting in exposure of NMDA receptors to accumulated glutamate, which leads to lethal elevation of intracellular calcium levels. The cascade of events initiated by this process also can induce apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      AMPA and kainate receptors are both coupled to sodium and potassium ion channels. Whereas NMDA receptors are always permeable to Ca(2+), cation permeability of AMPA receptors depends on subunit composition. Ca(2+) influx is differentially regulated by AMPA receptors compared to kainate receptors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oligodendroglia are particularly vulnerable to glutamate [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/55\">",
"     55",
"    </a>",
"    ]. Preoligodendrocyte subtypes O4 and O1+ express subunits for both the AMPA (GluR1, GluR2, GluR3, and GluR4) and kainate (KA1,",
"    <span class=\"nowrap\">",
"     GluR5/6,",
"    </span>",
"    and GLuR7) receptors but not NMDA receptors, whereas mature MBP+ oligodendrocytes have little to no expression of either NMDA receptors or non-NMDA receptors.",
"   </p>",
"   <p>",
"    Mature oligodendrocytes in mixed cocultures die after exposure to kainate, but AMPA receptors are the most important mediators of cellular demise, with kainate receptors playing a smaller role [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/56\">",
"     56",
"    </a>",
"    ]. In this paradigm, cell death occurs predominantly by necrosis, not apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/56\">",
"     56",
"    </a>",
"    ]. However, there is evidence that mature oligodendrocytes expressing myelin basic protein are resistant to excitotoxic injury produced by kainate, whereas earlier stages in the oligodendrocyte lineage are vulnerable to this insult [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Nitric oxide and oxygen-free radicals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide (NO) and oxygen-free radicals appear to play important roles in brain injury induced by hypoxia-ischemia.",
"   </p>",
"   <p>",
"    Nitric oxide can behave as an oxidant as well as an antioxidant. Under pathological conditions there is excess NO production that results in cell toxicity through direct biochemical effects or through reactive nitrogen species that is formed from the reaction of NO and reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nitric oxide is synthesized by nitric oxide synthase (NOS) from L-arginine in the presence of essential cofactor, tetrahydrobiopterin. Nitric oxide synthase exists in three isoforms: neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS).",
"   </p>",
"   <p>",
"    Available evidence suggests that eNOS has a predominant protective role in hypoxia-ischemia, whereas nNOS and iNOS have a facilitative role.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histopathologic studies have shown that nNOS knockout neonatal animals are protected from focal hypoxic-ischemic-induced histopathologic brain damage [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, iNOS knockout animals show a reduction of focal ischemic brain damage and locomotor deficits [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Animals lacking the eNOS gene have enlarged cerebral infarcts after ischemic injury [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of specific NOS inhibitors as neuroprotectants is currently being studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PERINATAL STROKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal stroke is an increasingly recognized entity in term newborns with encephalopathy and cerebral palsy. Perinatal stroke occurs about once in 4000 births. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=see_link&amp;anchor=H2#H2\">",
"     \"Stroke in the newborn\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of infants with ischemic perinatal stroke develop neonatal seizures. Additional signs of neonatal encephalopathy may also be present, such as lethargy, hypotonia, feeding difficulties, or apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A specific cause for perinatal stroke is not identified in most affected newborns. Factors contributing to the risk include maternal conditions such as prothrombotic disorder and cocaine abuse; placental complications such as preeclampsia, chorioamnionitis and placental vasculopathy; and newborn conditions such as prothrombotic disorders, congenital heart disease, meningitis, and systemic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/63\">",
"     63",
"    </a>",
"    ]. During the delivery process, an infant may develop a cervical arterial dissection that leads to stroke.",
"   </p>",
"   <p>",
"    Potential long-term sequelae of perinatal arterial stroke include cerebral palsy, cognitive deficits, hemiparesis, and epilepsy. However, development is normal in approximately 19 to 33 percent of infants with neonatal ischemic infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=see_link&amp;anchor=H15#H15\">",
"     \"Stroke in the newborn\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGRESSIVE ENCEPHALOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;One must always consider the possibility of progressive disorders in cases of neonatal encephalopathy. These include metabolic, neurodegenerative, infectious or toxic etiologies that are rare, with a combined incidence of approximately 6 per 10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/64\">",
"     64",
"    </a>",
"    ], but a much higher mortality rate than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/65\">",
"     65",
"    </a>",
"    ]. A history of parental consanguinity is associated with a marked increase in the risk of progressive encephalopathy, and thus is an important clue suggesting metabolic and neurodegenerative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of metabolic and genetic abnormalities may cause neonatal encephalopathy. Inborn errors of metabolism that present in the newborn period typically share strikingly similar clinical features, including decreased level of consciousness, seizures, poor feeding, hypotonia, and vomiting. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disorders of amino acid metabolism (eg, maple syrup urine disease, phenylketonuria, nonketotic hyperglycinemia) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27590?source=see_link\">",
"       \"Overview of maple syrup urine disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=see_link\">",
"       \"Overview of phenylketonuria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperammonemia (eg, urea cycle defects) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=see_link\">",
"       \"Urea cycle disorders: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neonatal hypoglycemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link\">",
"       \"Neonatal hypoglycemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Organic acidemias (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"       \"Organic acidemias\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mitochondrial disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"       \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe peroxisomal disorders (eg, Zellweger syndrome) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link\">",
"       \"Peroxisomal disorders\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific disorders such as multiple sulfite oxidase deficiency may produce neuroimaging and clinical findings that very closely mimic hypoxic-ischemic brain injury. Genetic disorders such as Prader-Willi and chromosomal abnormalities may also present with newborn encephalopathy. However, metabolic and genetic disorders account only for a very small proportion of cases of neonatal encephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that neonatal encephalopathy is an umbrella term that includes any type of brain injury or insult resulting in central nervous system dysfunction, the list of brain disorders that can cause neonatal encephalopathy is quite long [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/67\">",
"     67",
"    </a>",
"    ]. As examples, brain anomalies, intracranial hemorrhage and infection can all lead to seizures and encephalopathy in the newborn period.",
"   </p>",
"   <p>",
"    Intraventricular hemorrhage in term infants may cause symptoms of neonatal encephalopathy, and is often related to sinovenous thrombosis as opposed to the more typical intraventricular hemorrhage associated with germinal matrix hemorrhage seen in preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/68\">",
"     68",
"    </a>",
"    ]. Intracerebral hemorrhage in a term infant is often idiopathic, but may be related to birth trauma, congenital vascular malformation, or a clotting disorder.",
"   </p>",
"   <p>",
"    Finally, a variety of maternal toxins can cause encephalopathy in the newborn period. For instance, passive addiction to narcotics, barbiturates, alcohol, tricyclic antidepressants, and serotonin reuptake inhibitors can produce seizures and encephalopathy in the neonate [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30953/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonatal encephalopathy is the preferred terminology to describe central nervous system dysfunction in the newborn period. It can result from a wide variety of conditions but often remains unexplained. The nature of brain injury causing neurologic impairment in a newborn is poorly understood. Hypoxia-ischemia is only one of many possible contributors to neonatal encephalopathy. Whether a particular newborn's encephalopathy can be attributed to hypoxic-ischemic brain injury is often controversial. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 70 percent of neonatal encephalopathy cases are associated with events arising before the onset of labor (",
"      <a class=\"graphic graphic_figure graphicRef70341 \" href=\"UTD.htm?18/53/19295\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef60212 \" href=\"UTD.htm?27/38/28271\">",
"       figure 2",
"      </a>",
"      ). These include (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Antepartum'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Maternal factors, including unemployment, family history of seizures or neurologic disorder, infertility treatment, and thyroid disease",
"     </li>",
"     <li>",
"      Placental conditions, including severe preeclampsia, post-dates, and abnormal appearance of the placenta",
"     </li>",
"     <li>",
"      Fetal problems, such as intrauterine growth restriction",
"      <br/>",
"      <br/>",
"      Of these, intrauterine growth restriction is the strongest risk factor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrapartum risk factors for neonatal encephalopathy include the following (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Intrapartum'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Persistent occipitoposterior position",
"     </li>",
"     <li>",
"      Maternal fever",
"     </li>",
"     <li>",
"      Emergency cesarean delivery",
"     </li>",
"     <li>",
"      Operative vaginal delivery",
"     </li>",
"     <li>",
"      Acute intrapartum events",
"      <br/>",
"      <br/>",
"      An acute (ie, sentinel) intrapartum event, such as a placental abruption or uterine rupture, confers an increased risk of neonatal encephalopathy, but is present in only a small minority of infants with neonatal encephalopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal hypoxic-ischemic brain injury and subsequent hypoxic-ischemic encephalopathy (HIE) can occur by one or more of the following mechanisms (",
"      <a class=\"graphic graphic_table graphicRef67794 \" href=\"UTD.htm?36/17/37147\">",
"       table 3",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Hypoxic-ischemic injury'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Maternal, via impaired oxygenation (eg, asthma, pulmonary embolism, pneumonia)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inadequate perfusion of the maternal placenta (eg, cardiorespiratory arrest, maternal hypotension, preeclampsia, chronic vascular disease)",
"     </li>",
"     <li>",
"      Placental (eg, abruptio placenta, tight nuchal cord, cord prolapsed, true knot, uterine rupture)",
"     </li>",
"     <li>",
"      Fetal, via impaired fetal",
"      <span class=\"nowrap\">",
"       oxygenation/perfusion",
"      </span>",
"      (eg, fetomaternal hemorrhage, fetal thrombosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perinatal stroke is an increasingly recognized entity in term newborns with encephalopathy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Perinatal stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rare progressive metabolic and neurodegenerative disorders can underlie neonatal encephalopathy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Progressive encephalopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/1\">",
"      Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol 1976; 33:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/2\">",
"      Ferriero DM. Neonatal brain injury. N Engl J Med 2004; 351:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/3\">",
"      Dammann O, Ferriero D, Gressens P. Neonatal encephalopathy or hypoxic-ischemic encephalopathy? Appropriate terminology matters. Pediatr Res 2011; 70:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/4\">",
"      Sartwelle TP. Defending a neurologic birth injury. Asphyxia neonatorum redux. J Leg Med 2009; 30:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/5\">",
"      Badawi N, Kurinczuk JJ, Keogh JM, et al. Antepartum risk factors for newborn encephalopathy: the Western Australian case-control study. BMJ 1998; 317:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/6\">",
"      Bartha AI, Foster-Barber A, Miller SP, et al. Neonatal encephalopathy: association of cytokines with MR spectroscopy and outcome. Pediatr Res 2004; 56:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/7\">",
"      Wu Y. Brain injury in newborn babies: we can't afford to get it wrong. Ann Neurol 2012; 72:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/8\">",
"      Volpe JJ. Neonatal encephalopathy: an inadequate term for hypoxic-ischemic encephalopathy. Ann Neurol 2012; 72:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/9\">",
"      Bax M, Nelson KB. Birth asphyxia: a statement. World Federation of Neurology Group. Dev Med Child Neurol 1993; 35:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/10\">",
"      Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Number 326, December 2005. Inappropriate use of the terms fetal distress and birth asphyxia. Obstet Gynecol 2005; 106:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/11\">",
"      Gunn AJ, Bennet L. Timing of injury in the fetus and neonate. Curr Opin Obstet Gynecol 2008; 20:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/12\">",
"      Cowan F, Rutherford M, Groenendaal F, et al. Origin and timing of brain lesions in term infants with neonatal encephalopathy. Lancet 2003; 361:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/13\">",
"      American Collge of Obstetricians and Gynecologists (ACOG). Neonatal encephalopathy and cerebral palsy: executive summary. Obstet Gynecol 2004; 103:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/14\">",
"      Holcroft CJ, Askin FB, Patra A, et al. Are histopathologic chorioamnionitis and funisitis associated with metabolic acidosis in the preterm fetus? Am J Obstet Gynecol 2004; 191:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/15\">",
"      Badawi N, Kurinczuk JJ, Keogh JM, et al. Intrapartum risk factors for newborn encephalopathy: the Western Australian case-control study. BMJ 1998; 317:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/16\">",
"      Nelson KB, Bingham P, Edwards EM, et al. Antecedents of neonatal encephalopathy in the Vermont Oxford Network Encephalopathy Registry. Pediatrics 2012; 130:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/17\">",
"      Bukowski R, Burgett AD, Gei A, et al. Impairment of fetal growth potential and neonatal encephalopathy. Am J Obstet Gynecol 2003; 188:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/18\">",
"      McDonald DG, Kelehan P, McMenamin JB, et al. Placental fetal thrombotic vasculopathy is associated with neonatal encephalopathy. Hum Pathol 2004; 35:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/19\">",
"      Redline RW. Severe fetal placental vascular lesions in term infants with neurologic impairment. Am J Obstet Gynecol 2005; 192:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/20\">",
"      Chang T, Reyes C, Teng J, et al. Neonatal encephalopathy, sentinel events, and the placenta. J Neonatal Perinatal Med 2012; 5:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/21\">",
"      Redline RW. Cerebral palsy in term infants: a clinicopathologic analysis of 158 medicolegal case reviews. Pediatr Dev Pathol 2008; 11:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/22\">",
"      Lieberman E, Lang J, Richardson DK, et al. Intrapartum maternal fever and neonatal outcome. Pediatrics 2000; 105:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/23\">",
"      Blume HK, Li CI, Loch CM, Koepsell TD. Intrapartum fever and chorioamnionitis as risks for encephalopathy in term newborns: a case-control study. Dev Med Child Neurol 2008; 50:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/24\">",
"      Impey LW, Greenwood CE, Black RS, et al. The relationship between intrapartum maternal fever and neonatal acidosis as risk factors for neonatal encephalopathy. Am J Obstet Gynecol 2008; 198:49.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/25\">",
"      Shalak LF, Perlman JM, Jackson GL, Laptook AR. Depression at birth in term infants exposed to maternal chorioamnionitis: does neonatal fever play a role? J Perinatol 2005; 25:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/26\">",
"      Grether JK, Nelson KB. Maternal infection and cerebral palsy in infants of normal birth weight. JAMA 1997; 278:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/27\">",
"      Wu YW, Colford JM Jr. Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis. JAMA 2000; 284:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/28\">",
"      Wu YW, Escobar GJ, Grether JK, et al. Chorioamnionitis and cerebral palsy in term and near-term infants. JAMA 2003; 290:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/29\">",
"      Aly H, Khashaba MT, El-Ayouty M, et al. IL-1beta, IL-6 and TNF-alpha and outcomes of neonatal hypoxic ischemic encephalopathy. Brain Dev 2006; 28:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/30\">",
"      Odd DE, Lewis G, Whitelaw A, Gunnell D. Resuscitation at birth and cognition at 8 years of age: a cohort study. Lancet 2009; 373:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/31\">",
"      Becher JC, Bell JE, Keeling JW, et al. The Scottish perinatal neuropathology study: clinicopathological correlation in early neonatal deaths. Arch Dis Child Fetal Neonatal Ed 2004; 89:F399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/32\">",
"      Bejar R, Vigliocco G, Gramajo H, et al. Antenatal origin of neurologic damage in newborn infants. II. Multiple gestations. Am J Obstet Gynecol 1990; 162:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/33\">",
"      Logitharajah P, Rutherford MA, Cowan FM. Hypoxic-ischemic encephalopathy in preterm infants: antecedent factors, brain imaging, and outcome. Pediatr Res 2009; 66:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/34\">",
"      Okereafor A, Allsop J, Counsell SJ, et al. Patterns of brain injury in neonates exposed to perinatal sentinel events. Pediatrics 2008; 121:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/35\">",
"      Reddy K, Mallard C, Guan J, et al. Maturational change in the cortical response to hypoperfusion injury in the fetal sheep. Pediatr Res 1998; 43:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/36\">",
"      Keunen H, Blanco CE, van Reempts JL, Hasaart TH. Absence of neuronal damage after umbilical cord occlusion of 10, 15, and 20 minutes in midgestation fetal sheep. Am J Obstet Gynecol 1997; 176:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/37\">",
"      Windle WF. Brain damage at birth. Functional and structural modifications with time. JAMA 1968; 206:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/38\">",
"      Juul SE, Aylward E, Richards T, et al. Prenatal cord clamping in newborn Macaca nemestrina: a model of perinatal asphyxia. Dev Neurosci 2007; 29:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/39\">",
"      Usta IM, Mercer BM, Sibai BM. Current obstetrical practice and umbilical cord prolapse. Am J Perinatol 1999; 16:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/40\">",
"      Poetker DM, Rijhsinghani A. Fetal survival after umbilical cord prolapse for more than three days. A case report. J Reprod Med 2001; 46:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/41\">",
"      Derrick M, Luo NL, Bregman JC, et al. Preterm fetal hypoxia-ischemia causes hypertonia and motor deficits in the neonatal rabbit: a model for human cerebral palsy? J Neurosci 2004; 24:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/42\">",
"      Schober ME, McKnight RA, Yu X, et al. Intrauterine growth restriction due to uteroplacental insufficiency decreased white matter and altered NMDAR subunit composition in juvenile rat hippocampi. Am J Physiol Regul Integr Comp Physiol 2009; 296:R681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/43\">",
"      Morrison JL. Sheep models of intrauterine growth restriction: fetal adaptations and consequences. Clin Exp Pharmacol Physiol 2008; 35:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/44\">",
"      Mart&iacute;nez-Biarge M, Garc&iacute;a-Alix A, Garc&iacute;a-Benasach F, et al. Neonatal neurological morbidity associated with uterine rupture. J Perinat Med 2008; 36:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/45\">",
"      Murphy DJ, Sellers S, MacKenzie IZ, et al. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet 1995; 346:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/46\">",
"      Back SA, Luo NL, Borenstein NS, et al. Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury. J Neurosci 2001; 21:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/47\">",
"      Volpe JJ. Perinatal brain injury: from pathogenesis to neuroprotection. Ment Retard Dev Disabil Res Rev 2001; 7:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/48\">",
"      Tan S, Zhou F, Nielsen VG, et al. Sustained hypoxia-ischemia results in reactive nitrogen and oxygen species production and injury in the premature fetal rabbit brain. J Neuropathol Exp Neurol 1998; 57:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/49\">",
"      Tan S, Parks DA. Preserving brain function during neonatal asphyxia. Clin Perinatol 1999; 26:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/50\">",
"      Drobyshevsky A, Derrick M, Prasad PV, et al. Fetal brain magnetic resonance imaging response acutely to hypoxia-ischemia predicts postnatal outcome. Ann Neurol 2007; 61:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/51\">",
"      Drobyshevsky A, Luo K, Derrick M, et al. Motor deficits are triggered by reperfusion-reoxygenation injury as diagnosed by MRI and by a mechanism involving oxidants. J Neurosci 2012; 32:5500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/52\">",
"      Monaghan DT, Holets VR, Toy DW, Cotman CW. Anatomical distributions of four pharmacologically distinct 3H-L-glutamate binding sites. Nature 1983; 306:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/53\">",
"      Mayer ML, Westbrook GL, Guthrie PB. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature 1984; 309:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/54\">",
"      Ankarcrona M, Dypbukt JM, Bonfoco E, et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995; 15:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/55\">",
"      Jensen FE. Role of glutamate receptors in periventricular leukomalacia. J Child Neurol 2005; 20:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/56\">",
"      Leuchtmann EA, Ratner AE, Vijitruth R, et al. AMPA receptors are the major mediators of excitotoxic death in mature oligodendrocytes. Neurobiol Dis 2003; 14:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/57\">",
"      Rosenberg PA, Dai W, Gan XD, et al. Mature myelin basic protein-expressing oligodendrocytes are insensitive to kainate toxicity. J Neurosci Res 2003; 71:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/58\">",
"      Beckman JS. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J Dev Physiol 1991; 15:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/59\">",
"      Ferriero DM, Holtzman DM, Black SM, Sheldon RA. Neonatal mice lacking neuronal nitric oxide synthase are less vulnerable to hypoxic-ischemic injury. Neurobiol Dis 1996; 3:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/60\">",
"      Iadecola C, Zhang F, Casey R, et al. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 1997; 17:9157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/61\">",
"      Huang Z, Huang PL, Ma J, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab 1996; 16:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/62\">",
"      Wu YW, March WM, Croen LA, et al. Perinatal stroke in children with motor impairment: a population-based study. Pediatrics 2004; 114:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/63\">",
"      Wu YW, Lynch JK, Nelson KB. Perinatal arterial stroke: understanding mechanisms and outcomes. Semin Neurol 2005; 25:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/64\">",
"      Stromme P, Kanavin OJ, Abdelnoor M, et al. Incidence rates of progressive childhood encephalopathy in Oslo, Norway: a population based study. BMC Pediatr 2007; 7:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/65\">",
"      Str&oslash;mme P, Magnus P, Kanavin &Oslash;J, et al. Mortality in childhood progressive encephalopathy from 1985 to 2004 in Oslo, Norway: a population-based study. Acta Paediatr 2008; 97:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/66\">",
"      Str&oslash;mme P, Suren P, Kanavin OJ, et al. Parental consanguinity is associated with a seven-fold increased risk of progressive encephalopathy: a cohort study from Oslo, Norway. Eur J Paediatr Neurol 2010; 14:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/67\">",
"      Johnston MV, Fatemi A, Wilson MA, Northington F. Treatment advances in neonatal neuroprotection and neurointensive care. Lancet Neurol 2011; 10:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/68\">",
"      Wu YW, Hamrick SE, Miller SP, et al. Intraventricular hemorrhage in term neonates caused by sinovenous thrombosis. Ann Neurol 2003; 54:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30953/abstract/69\">",
"      Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365:482.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6205 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30953=[""].join("\n");
var outline_f30_14_30953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Timing of insult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antepartum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intrapartum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HYPOXIC-ISCHEMIC INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antecedent events and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Level and duration of hypoxia-ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vulnerable regions of developing brain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mechanisms of neuronal injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Excitotoxic injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Nitric oxide and oxygen-free radicals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PERINATAL STROKE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGRESSIVE ENCEPHALOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6205\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6205|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/53/19295\" title=\"figure 1\">",
"      Timing anatomic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/38/28271\" title=\"figure 2\">",
"      Anatomic etiologic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/7/41072\" title=\"figure 3\">",
"      HIE outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/55/18303\" title=\"figure 4\">",
"      Timeline injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/62/11232\" title=\"figure 5\">",
"      HIE pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6205|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/27/6587\" title=\"table 1\">",
"      Criteria for asphyxial CP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/10/10411\" title=\"table 2\">",
"      Nonasphyxial events and CP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/17/37147\" title=\"table 3\">",
"      Mechanisms HIE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27590?source=related_link\">",
"      Overview of maple syrup urine disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=related_link\">",
"      Overview of phenylketonuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21929?source=related_link\">",
"      Placental pathology in cases of neurologically impaired infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=related_link\">",
"      Stroke in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=related_link\">",
"      Urea cycle disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_14_30954="Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging";
var content_f30_14_30954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/14/30954/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30954/contributors\">",
"     Stephen I Rennard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/14/30954/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30954/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/14/30954/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/14/30954/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/14/30954/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic obstructive pulmonary disease (COPD) is a common respiratory condition involving the airways and characterized by airflow limitation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It affects more than 5 percent of the population and is associated with high morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/3\">",
"     3",
"    </a>",
"    ]. It is the third-ranked cause of death in the United States, killing more than 120,000 individuals each year [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/4\">",
"     4",
"    </a>",
"    ]. As a consequence of its high prevalence and chronicity, COPD causes high resource utilization with frequent clinician office visits, frequent hospitalizations due to acute exacerbations, and the need for chronic therapy (eg, supplemental oxygen therapy, medication) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Correct diagnosis of COPD is important because appropriate management can decrease symptoms (especially dyspnea), reduce the frequency and severity of exacerbations, improve health status, improve exercise capacity, and prolong survival [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definition, clinical manifestations, diagnostic evaluation, and staging of COPD are discussed in this topic review. The risk factors, natural history, prognosis, and treatment of COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6089?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Risk factors and risk reduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35351?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of COPD and its subtypes (emphysema, chronic bronchitis, and chronic obstructive asthma) and the interrelationships between the closely related disorders that cause airflow limitation provide a foundation for understanding the spectrum of patient presentations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263049240\">",
"    <span class=\"h2\">",
"     COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Global Initiative for Chronic Obstructive Lung Disease (GOLD) &ndash; a project initiated by the National Heart, Lung, and Blood Institute (NHLBI) and the World Health Organization (WHO) defines COPD as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &ldquo;Chronic obstructive pulmonary disease (COPD), a common preventable and treatable disease, is characterized by airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263049277\">",
"    <span class=\"h2\">",
"     Chronic bronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic bronchitis is defined as a chronic productive cough for three months in each of two successive years in a patient in whom other causes of chronic cough (eg, bronchiectasis) have been excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/7\">",
"     7",
"    </a>",
"    ]. It may precede or follow development of airflow limitation. This definition has been used in many studies, despite the arbitrarily selected symptom duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263049416\">",
"    <span class=\"h2\">",
"     Emphysema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emphysema is defined by abnormal and permanent enlargement of the airspaces distal to the terminal bronchioles that is accompanied by destruction of the airspace walls, without obvious fibrosis (ie, there is no fibrosis visible to the naked eye) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/8\">",
"     8",
"    </a>",
"    ]. Exclusion of obvious fibrosis was intended to distinguish the alveolar destruction due to emphysema from that due to the interstitial pneumonias. However, many studies have found increased collagen in the lungs of patients with mild COPD, indicating that fibrosis can be a component of emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. While emphysema can exist in individuals who do not have airflow obstruction, it is more common among patients who have moderate or severe airflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The various subtypes of emphysema (eg, proximal acinar, panacinar, distal acinar) are described below. (See",
"    <a class=\"local\" href=\"#H18807517\">",
"     'Pathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263049549\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Global Initiative for Asthma gives the following definition of asthma. &ldquo;Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation is associated with airway responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. These episodes are usually associated with widespread, but variable, airflow obstruction within the lung that is often reversible either spontaneously or with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/13\">",
"     13",
"    </a>",
"    ].&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Interrelationships of COPD subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early definitions of COPD distinguished different types (ie, chronic bronchitis, emphysema, asthma), a distinction that is not included in the current definition [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. However, individual patients present with a spectrum of manifestations of COPD and related processes, so understanding the types of COPD, as illustrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef66708 \" href=\"UTD.htm?35/52/36686\">",
"     figure 1",
"    </a>",
"    ), can be helpful diagnostically. Important points about their interrelationship include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with asthma whose airflow obstruction is completely reversible are not considered to have COPD (subset nine in the figure).",
"     </li>",
"     <li>",
"      Patients with asthma whose airflow obstruction does not remit completely are considered to have COPD (subsets six, seven, and eight in the figure). The etiology and pathogenesis of the COPD in such patients may be different from that of patients with chronic bronchitis or emphysema.",
"     </li>",
"     <li>",
"      Chronic bronchitis and emphysema with airflow obstruction commonly occur together (subset five in the figure) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/17\">",
"       17",
"      </a>",
"      ]. Some of these patients may also have asthma (subset eight in the figure).",
"     </li>",
"     <li>",
"      Individuals with asthma may develop a chronic productive cough, either spontaneously or due to exposure (eg, cigarette smoke, allergen). Such patients are often referred to as having asthmatic bronchitis, although this terminology has not been officially endorsed in clinical practice guidelines (subset six in the figure).",
"     </li>",
"     <li>",
"      Persons with chronic bronchitis, emphysema, or both are not considered to have COPD unless they have airflow obstruction (subsets one, two, and eleven in the figure) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with airflow obstruction due to diseases that have a known etiology or a specific pathology (eg, cystic fibrosis, bronchiectasis, obliterative bronchiolitis) are not considered to have COPD (subset 10 in the figure). However, these exclusions are loosely defined [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consistent with the idea that significant overlap exists among the different types of COPD, many individuals have bronchial inflammation with features of both asthma and chronic",
"    <span class=\"nowrap\">",
"     bronchitis/emphysema",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/21\">",
"     21",
"    </a>",
"    ]. Similarly, the nature of the bronchial inflammation varies widely even among individuals with a single type of COPD. A number of initiatives are in progress to provide rigorous phenotyping of COPD patients in order to define more homogeneous groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18807517\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant pathologic changes of COPD are found in the airways, but changes are also seen in the lung parenchyma and pulmonary vasculature. In an individual, the pattern of pathologic changes depends on the underlying disease (eg, chronic bronchitis, emphysema, alpha-1 antitrypsin deficiency), possibly individual susceptibility, and disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18484273\">",
"    <span class=\"h2\">",
"     Airways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airways abnormalities in COPD include chronic inflammation, increased numbers of goblet cells, mucus gland hyperplasia, fibrosis, narrowing and reduction in the number of small airways, and airway collapse due to the loss of tethering caused by alveolar wall destruction in emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/12\">",
"     12",
"    </a>",
"    ]. Chronic inflammation in chronic bronchitis and emphysema is characterized by the presence of CD8+ T-lymphocytes, neutrophils, and CD68+",
"    <span class=\"nowrap\">",
"     monocytes/macrophages",
"    </span>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef69029 \" href=\"UTD.htm?7/52/8005\">",
"     picture 1",
"    </a>",
"    ) in the airways [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. In comparison, the bronchial inflammation of asthma is characterized by the presence of CD4+ T-lymphocytes, eosinophils, and increased interleukin (IL)-4 and IL-5 (",
"    <a class=\"graphic graphic_algorithm graphicRef79740 \" href=\"UTD.htm?2/57/2974\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/21,27,28\">",
"     21,27,28",
"    </a>",
"    ]. Among patients with chronic bronchitis who have mucus hypersecretion, an increased number of goblet cells and enlarged submucosal glands are typically seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18484281\">",
"    <span class=\"h2\">",
"     Lung parenchyma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emphysema affects the structures distal to the terminal bronchiole, consisting of the respiratory bronchiole, alveolar ducts, alveolar sacs, and alveoli, known collectively as the acinus. These structures in combination with their associated capillaries and interstitium form the lung parenchyma. The part of the acinus that is affected by permanent dilation or destruction determines the subtype of emphysema.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proximal acinar (also known as centrilobular) emphysema refers to abnormal dilation or destruction of the respiratory bronchiole, the central portion of the acinus. It is commonly associated with cigarette smoking, but can also be seen in coal workers&rsquo; pneumoconiosis.",
"     </li>",
"     <li>",
"      Panacinar emphysema refers to enlargement or destruction of all parts of the acinus. Diffuse panacinar emphysema is most commonly associated with alpha-1 antitrypsin deficiency, although it can be seen in combination with proximal emphysema in smokers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In distal acinar (also known as paraseptal) emphysema, the alveolar ducts are predominantly affected. Distal acinar emphysema may occur alone or in combination with proximal acinar and panacinar emphysema. When it occurs alone, the usual association is spontaneous pneumothorax in a young adult. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=see_link\">",
"       \"Primary spontaneous pneumothorax in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18484288\">",
"    <span class=\"h2\">",
"     Pulmonary vasculature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the pulmonary vasculature include intimal hyperplasia and smooth muscle",
"    <span class=\"nowrap\">",
"     hypertrophy/hyperplasia",
"    </span>",
"    thought to be due to chronic hypoxic vasoconstriction of the small pulmonary arteries. Destruction of alveoli due to emphysema can lead to loss of the associated areas of the pulmonary capillary bed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20447432\">",
"    <span class=\"h2\">",
"     Smoking and inhalational exposure history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important risk factor for COPD is cigarette smoking and the amount and duration of smoking contribute to disease severity. Thus, a key step in the evaluation of patients with suspected COPD is to ascertain the number of pack years smoked (packs of cigarettes per day multiplied by the number of years), as the majority (80 percent) of patients with COPD have a history of cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. It is useful to ask the age of starting and the age of quitting, as patients may underestimate the number of years they smoked. With enough smoking, almost all smokers will develop measurably reduced lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/5\">",
"     5",
"    </a>",
"    ]. While studies have shown an overall &ldquo;dose-response curve&rdquo; for smoking and lung function, some individuals develop severe disease with fewer pack years and others have minimal to no symptoms despite many pack years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact threshold for the",
"    <span class=\"nowrap\">",
"     duration/intensity",
"    </span>",
"    of cigarette smoking that will result in COPD varies from one individual to another. In the absence of a",
"    <span class=\"nowrap\">",
"     genetic/environmental/occupational",
"    </span>",
"    predisposition, smoking less than 10 to 15 pack years of cigarettes is unlikely to result in COPD. On the other hand, the single best variable for predicting which adults will have airflow obstruction on spirometry is a history of more than 40 pack years of smoking (positive likelihood ratio [LR], 12 [95% CI, 2.7-50]) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chronologically taken",
"    <span class=\"nowrap\">",
"     environmental/occupational",
"    </span>",
"    history may disclose other important risk factors for COPD, such as exposure to fumes or organic or inorganic dusts. These exposures help to explain the 20 percent of patients with COPD (defined by lung function alone) and the 20 percent of patients who die from COPD who never smoked [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/30,33,34\">",
"     30,33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6089?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Risk factors and risk reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Symptoms and pattern of onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three cardinal symptoms of COPD are dyspnea, chronic cough, and sputum production and the most common early symptom is exertional dyspnea. Less common symptoms include wheezing and chest tightness (",
"    <a class=\"graphic graphic_table graphicRef53303 \" href=\"UTD.htm?43/20/44364\">",
"     table 1A",
"    </a>",
"    ). However, any of these symptoms may develop independently and with variable intensity.",
"   </p>",
"   <p>",
"    There are three typical ways in which patients with COPD present [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have an extremely sedentary lifestyle but few complaints require careful questioning to elicit a history that is suggestive of COPD. Some patients unknowingly avoid exertional dyspnea by shifting their expectations and limiting their activity. They may be unaware of the extent of their limitations or that their limitations are due to respiratory symptoms, although they may complain of fatigue.",
"     </li>",
"     <li>",
"      Patients who present with respiratory symptoms generally complain of dyspnea and chronic cough. The dyspnea may initially be noticed only during exertion. However, it eventually becomes noticeable with progressively less exertion or even at rest. The chronic cough is characterized by the insidious onset of sputum production, which occurs in the morning initially, but may progress to occur throughout the day. The daily volume rarely exceeds 60 mL. The sputum is usually mucoid, but becomes purulent during exacerbations.",
"     </li>",
"     <li>",
"      Patients who present with episodes of increased cough, purulent sputum, wheezing, and dyspnea that occur intermittently, with or without fever. Diagnosis can be problematic in such patients. The combination of wheezing plus dyspnea may lead to an incorrect diagnosis of asthma. Conversely, other illnesses with similar manifestations are often incorrectly diagnosed as a COPD exacerbation (eg, heart failure, bronchiectasis, bronchiolitis) (",
"      <a class=\"graphic graphic_table graphicRef51974 \" href=\"UTD.htm?13/13/13533\">",
"       table 2",
"      </a>",
"      ). The interval between exacerbations decreases as the severity of the COPD increases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"       \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 62 percent of patients with moderate to severe COPD report variability in symptoms (eg, dyspnea, cough, sputum, wheezing, or chest tightness) over the course of the day or week-to-week; morning is typically the worst time of day [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with COPD may experience weight gain (due to activity limitations), weight loss (possibly due to dyspnea while eating), limitation of activity (including sexual), cough syncope, or feelings of depression or anxiety. Weight loss generally reflects more advanced disease and is associated with a worse prognosis. However, the majority of COPD patients are overweight or obese.",
"   </p>",
"   <p>",
"    Comorbid diseases that may accompany COPD include lung cancer, coronary heart disease, osteoporosis, metabolic syndrome, skeletal muscle weakness, depression, and cognitive dysfunction. Patients may also report a family history of COPD or other chronic respiratory illness [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/6,37-42\">",
"     6,37-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings on physical examination of the chest vary with the severity of the COPD (",
"    <a class=\"graphic graphic_table graphicRef53303 graphicRef61983 \" href=\"UTD.htm?41/42/42669\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early in the disease, the physical examination may be normal, or may show only prolonged expiration or wheezes on forced exhalation.",
"     </li>",
"     <li>",
"      As the severity of the airway obstruction increases, physical examination may reveal hyperinflation (eg, increased resonance to percussion), decreased breath sounds, wheezes, crackles at the lung bases,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      distant heart sounds [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/43\">",
"       43",
"      </a>",
"      ]. Features of severe disease include an increased anteroposterior diameter of the chest (&ldquo;barrel-shaped&rdquo; chest) and a depressed diaphragm with limited movement based on chest percussion.",
"     </li>",
"     <li>",
"      Patients with end-stage COPD may adopt positions that relieve dyspnea, such as leaning forward with arms outstretched and weight supported on the palms or elbows. This posture may be evident during the examination or may be suggested by the presence of callouses or swollen bursae on the extensor surfaces of forearms. Other physical examination findings include use of the accessory respiratory muscles of the neck and shoulder girdle, expiration through pursed lips, paradoxical retraction of the lower interspaces during inspiration (ie, Hoover's sign) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/44,45\">",
"       44,45",
"      </a>",
"      ], cyanosis, asterixis due to severe hypercapnia, and an enlarged, tender liver due to right heart failure. Neck vein distention may also be observed because of increased intrathoracic pressure, especially during expiration.",
"     </li>",
"     <li>",
"      Yellow nicotine stains on the fingers are a clue to ongoing and heavy cigarette smoking.",
"      <br/>",
"      <br/>",
"      Clubbing of the digits is not typical in COPD (even with associated hypoxemia) and suggests comorbidities such as lung cancer, interstitial lung disease, or bronchiectasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24425163\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for COPD is appropriate in adults who report dyspnea, chronic cough, chronic sputum production or have had a gradual decline in level of peak activity, particularly if they have a history of exposure to risk factors for the disease (eg, cigarette smoking, indoor biomass smoke) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/6,31\">",
"     6,31",
"    </a>",
"    ]. All patients are evaluated with spirometry and selected patients have laboratory testing and imaging studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6089?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Risk factors and risk reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24425398\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;No laboratory test is diagnostic for COPD, but certain tests are sometimes obtained to exclude other causes of dyspnea and comorbid diseases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment for anemia is an important step in the evaluation of dyspnea. Measurement of plasma brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) concentrations is useful as a component of the evaluation of suspected heart failure (HF). Blood glucose, urea nitrogen, creatinine, electrolytes, calcium, phosphorus, and thyroid stimulating hormone may be appropriate depending on the degree of clinical suspicion for an alternate diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link&amp;anchor=H18#H18\">",
"       \"Approach to the patient with dyspnea\", section on 'Laboratory testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among stable COPD patients with normal kidney function, an elevated serum bicarbonate may indirectly identify chronic hypercapnia. In the presence of chronic hypercapnia, the serum bicarbonate is typically increased due to a compensatory metabolic alkalosis (",
"      <a class=\"graphic graphic_figure graphicRef63315 \" href=\"UTD.htm?30/38/31341\">",
"       figure 2",
"      </a>",
"      ). Abnormal results must be confirmed with arterial blood gas measurement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link&amp;anchor=H12584082#H12584082\">",
"       \"Simple and mixed acid-base disorders\", section on 'Respiratory acid-base disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testing for alpha-1 antitrypsin (AAT) deficiency should be obtained in all symptomatic adults with persistent airflow obstruction on spirometry. Especially suggestive subsets include the presence of emphysema in a young individual (eg, age &le;45 years), emphysema in a nonsmoker or minimal smoker, emphysema characterized by predominantly basilar changes on the chest radiograph, or a family history of emphysema [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/46\">",
"       46",
"      </a>",
"      ]. However, AAT deficiency may be present in a patient with otherwise &ldquo;typical&rdquo; COPD. A serum level of AAT below 11",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      (~57",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      by nephelometry) in combination with a severe deficient genotype is diagnostic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function tests, particularly spirometry, are the cornerstone of the diagnostic evaluation of patients with suspected COPD. In addition, PFTs are used to determine the severity of the airflow limitation, assess the response to medications, and follow disease progression. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link\">",
"     \"Office spirometry\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27742482\">",
"    <span class=\"h3\">",
"     Spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating a patient for possible COPD, spirometry is performed pre and post bronchodilator administration (eg, inhalation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    400 microg) to determine whether airflow limitation is present and whether it is partially or fully reversible. Airflow limitation that is irreversible or only partially reversible with bronchodilator is suggestive of COPD rather than asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link&amp;anchor=H18#H18\">",
"     \"Office spirometry\", section on 'Post-bronchodilator spirometry'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most important values measured during spirometry are the forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) and the forced vital capacity (FVC). The postbronchodilator ratio of",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    determines whether airflow limitation is present; the postbronchodilator percent predicted value for FEV",
"    <sub>",
"     1",
"    </sub>",
"    determines the severity of airflow limitation as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef82690 \" href=\"UTD.htm?34/28/35275\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18484580\">",
"    <span class=\"h3\">",
"     Lower limit of normal FEV1/FVC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, a postbronchodilator",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio less than 0.70 has been considered diagnostic of airflow limitation. However, the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio decreases with age, so use of the fifth percentile lower limit of normal (LLN) of the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio, rather than the absolute value of &lt;0.70, has been advocated as a dividing point for the diagnosis of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/7,11,47-50\">",
"     7,11,47-50",
"    </a>",
"    ]. However, the distinction between the LLN and the fixed ratio as dividing points is unlikely to lead to major clinical problems because current recommendations combine physiologic assessment with assessment of symptoms and exacerbations in staging severity. Moreover, in a study of 13,847 subjects in whom an increased mortality was noted among those with an",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    &lt;0.70, but a normal LLN",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    when compared with those whose",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    was 0.70 or higher [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link&amp;anchor=H11#H11\">",
"     \"Office spirometry\", section on 'Ratio of FEV1/FVC'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18484573\">",
"    <span class=\"h3\">",
"     Forced expiratory volume in six seconds",
"    </span>",
"    &nbsp;&mdash;&nbsp;The forced expiratory volume in six seconds (FEV",
"    <sub>",
"     6",
"    </sub>",
"    ), obtained by stopping the expiratory effort after 6 seconds rather than at cessation of airflow, is an acceptable surrogate for the FVC [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. The advantages of the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FEV",
"     <sub>",
"      6",
"     </sub>",
"    </span>",
"    include less frustration by the patient and technician trying to achieve an end-of-test plateau, less chance of syncope, shorter testing time, and better repeatability, without loss of sensitivity or specificity. The appropriate lower limit of normal (LLN) for",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FEV",
"     <sub>",
"      6",
"     </sub>",
"    </span>",
"    from NHANES III should be used to diagnose airflow limitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link&amp;anchor=H9#H9\">",
"     \"Office spirometry\", section on 'Forced expiratory volume in 6 seconds'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link&amp;anchor=H11#H11\">",
"     \"Office spirometry\", section on 'Ratio of FEV1/FVC'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1675515\">",
"    <span class=\"h3\">",
"     Peak expiratory flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peak expiratory flow is often used as a measure of airflow limitation in asthma, but may underestimate the degree of airflow limitation in COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, a low peak flow is not specific for airflow limitation and requires corroboration with spirometry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27742489\">",
"    <span class=\"h3\">",
"     Lung volumes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung volume measurement is not needed for all patients with suspected COPD. However, when a reduced FVC is noted on postbronchodilator spirometry, lung volume measurement by body plethysmography is used to determine whether the reduction in FVC is due to airtrapping, hyperinflation, or a concomitant restrictive ventilatory defect. Decreased inspiratory capacity (IC) and vital capacity, accompanied by an increased total lung capacity (TLC), functional residual capacity (FRC), and residual volume (RV) are indicative of hyperinflation. An increased FRC with a normal TLC is indicative of air trapping without hyperinflation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of pulmonary function testing in adults\", section on 'Lung volumes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36454?source=see_link\">",
"     \"Dynamic hyperinflation in patients with COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27742496\">",
"    <span class=\"h3\">",
"     Diffusing capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diffusing capacity for carbon monoxide (DLCO) is an excellent index of the degree of anatomic emphysema in smokers with airflow limitation, but is not needed for routine assessment of COPD. The indications for performing a DLCO measurement include hypoxemia by pulse oximetry (eg, PaO",
"    <sub>",
"     2",
"    </sub>",
"    &lt;92 mmHg) and evaluation for lung resection or lung volume reduction surgery. The DLCO decreases in proportion to the severity of emphysema; however, it cannot be used to detect mild emphysema because it is neither a sensitive nor a specific test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263050352\">",
"    <span class=\"h3\">",
"     Arterial blood gases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulse oximetry, which is obtained in the majority of patients, has reduced the number of patients who require arterial blood gases (ABGs). However, pulse oximetry does not provide information about alveolar ventilation or hypercapnia (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;45 mmHg), and assessment of oxygenation by pulse oximetry may be inaccurate in the setting of an acute exacerbation of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link\">",
"     \"Pulse oximetry\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link\">",
"     \"Arterial blood gases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of oxygen in patients with hypercapnia\", section on 'Effects of hypercapnia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indications for measuring ABGs (eg, arterial oxygen tension [PaO",
"    <sub>",
"     2",
"    </sub>",
"    ], carbon dioxide tension [PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ], and acidity [pH]), which must be considered in the clinical context, include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) (eg, &lt;50 percent predicted)",
"     </li>",
"     <li>",
"      Low oxygen saturation by pulse oximetry (eg, &lt;92 percent)",
"     </li>",
"     <li>",
"      Depressed level of consciousness",
"     </li>",
"     <li>",
"      Acute exacerbation of COPD",
"     </li>",
"     <li>",
"      Assessment for hypercapnia in at risk patients 30 to 60 minutes after initiation of supplemental oxygen (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"       \"Use of oxygen in patients with hypercapnia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with mild to moderate COPD, arterial blood gases usually reveal mild or moderate hypoxemia without hypercapnia. As the disease progresses, the hypoxemia becomes more severe and hypercapnia may develop. Hypercapnia becomes progressively more likely when the forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) approaches or falls below one liter. Blood gas abnormalities worsen during acute exacerbations and may also worsen during exercise and sleep. The compensatory responses to acute and chronic respiratory acidosis are shown in the figure and discussed separately (",
"    <a class=\"graphic graphic_figure graphicRef79833 \" href=\"UTD.htm?41/44/42691\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link&amp;anchor=H12584090#H12584090\">",
"     \"Simple and mixed acid-base disorders\", section on 'Respiratory acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiography and computed tomography are typically performed in patients with COPD when the cause of dyspnea or sputum production is unclear and during acute exacerbations to exclude complicating processes (eg, pneumonia, pneumothorax, heart failure). However, imaging is not required to diagnose COPD. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main reason to obtain a chest radiograph when evaluating a patient for COPD is to exclude alternative diagnoses, evaluate for comorbidities (eg, lung cancer with airway obstruction, bronchiectasis, pleural disease, interstitial lung disease, heart failure), or when a change in symptoms suggests a complication of COPD (eg, pneumonia, pneumothorax). Plain chest radiographs have a poor sensitivity for detecting COPD. As an example, only about half of patients with COPD of moderate severity are identified as having COPD by a plain chest radiograph (ie, sensitivity of 50 percent).",
"   </p>",
"   <p>",
"    Radiographic features suggestive of COPD (usually seen in advanced disease) include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapidly tapering vascular shadows, increased radiolucency of the lung, a flat diaphragm, and a long, narrow heart shadow on a frontal radiograph (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65594 \" href=\"UTD.htm?39/47/40693\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A flat diaphragmatic contour and an increased retrosternal airspace on a lateral radiograph (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87221 \" href=\"UTD.htm?27/10/27813\">",
"       image 2",
"      </a>",
"      ). These findings are due to hyperinflation.",
"     </li>",
"     <li>",
"      Bullae, defined as radiolucent areas larger than one centimeter in diameter and surrounded by arcuate hairline shadows. They are due to locally severe disease, and may or may not be accompanied by widespread emphysema (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82207 \" href=\"UTD.htm?20/54/21349\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When advanced COPD leads to pulmonary hypertension and cor pulmonale, prominent hilar vascular shadows and encroachment of the heart shadow on the retrosternal space may be seen [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/57\">",
"       57",
"      </a>",
"      ]. The cardiac enlargement may become evident only by comparison with previous chest radiographs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"       \"Overview of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) has greater sensitivity and specificity than standard chest radiography for the detection of emphysema, but not chronic bronchitis or asthma. This is particularly true with high resolution CT (ie, collimation of 1 to 2 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .) However, CT scanning is not needed for the routine diagnosis of COPD. Usually, it is performed when a change in symptoms suggests a complication of COPD (eg, pneumonia, pneumothorax, giant bullae), an alternate diagnosis (eg, thromboembolic disease), or when a patient is being considered for lung volume reduction surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8136?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation and medical management of giant bullae in COPD\", section on 'Evaluation and diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=see_link&amp;anchor=H7#H7\">",
"     \"Lung volume reduction surgery in COPD\", section on 'Patient selection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain CT scan features can determine whether the emphysema is centriacinar (centrilobular) or panacinar, although this is usually not necessary for clinical management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Centriacinar emphysema occurs preferentially in the upper lobes and produces holes in the center of secondary pulmonary lobules. The walls of emphysematous spaces are usually imperceptible, but central vessels may be visible (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82308 \" href=\"UTD.htm?39/55/40819\">",
"       image 4",
"      </a>",
"      ). In contrast, the walls of cysts in pulmonary Langerhans histiocytosis, another cystic lung disease of cigarette smokers, are thicker (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72698 \" href=\"UTD.htm?20/37/21074\">",
"       image 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18807517\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Panacinar emphysema more commonly involves the lung bases and involves the entire secondary pulmonary lobule (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57950 \" href=\"UTD.htm?21/55/22386\">",
"       image 6",
"      </a>",
"      ). Panacinar emphysema can cause a generalized paucity of vascular structures. Among patients with alpha-1 antitrypsin deficiency, panacinar emphysema is the more common pattern. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paraseptal (distal acinar) emphysema produces small, subpleural collections of gas located in the periphery of the secondary pulmonary lobule (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53689 \" href=\"UTD.htm?36/6/36961\">",
"       image 7",
"      </a>",
"      ). It is considered to be the precursor of bullae (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60307 \" href=\"UTD.htm?5/6/5220\">",
"       image 8",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18807517\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Newer CT scanners with higher resolution and new analytical methods can resolve airway dimensions, although the clinical significance of these measures is undefined [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Quantitative parameters based on lung density, as measured by CT scan, have been established to gauge emphysema, but are currently used primarily as research tools.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of COPD is based upon the following findings [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of symptoms compatible with COPD (eg, dyspnea at rest or on exertion, cough with or without sputum production, progressive limitation of activity) are suggestive of the diagnosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Symptoms and pattern of onset'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spirometry showing airflow limitation (ie, a",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      ratio less than 0.70 or less than the lower limit of normal [LLN] PLUS an FEV",
"      <sub>",
"       1",
"      </sub>",
"      less than 80 percent of predicted) that is incompletely reversible with inhaled bronchodilator (",
"      <a class=\"graphic graphic_table graphicRef53303 graphicRef61983 \" href=\"UTD.htm?41/42/42669\">",
"       table 1A-B",
"      </a>",
"      ) is the hallmark of the diagnosis of COPD. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pulmonary function tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Absence of an alternative explanation for the symptoms and airflow limitation (",
"      <a class=\"graphic graphic_table graphicRef51974 \" href=\"UTD.htm?13/13/13533\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/11\">",
"       11",
"      </a>",
"      ]. The differential diagnosis of COPD is discussed below. (See",
"      <a class=\"local\" href=\"#H263049556\">",
"       'Differential diagnosis'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"       \"Approach to the patient with dyspnea\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After confirming the presence of COPD, the next step is to consider the cause. For the majority of patients, the etiology is long-term cigarette smoking. However, it is important to review with the patient whether underlying asthma, workplace exposures, indoor use of biomass fuel, a prior history of tuberculosis, or familial predisposition is contributory, because mitigation of ongoing exposures may reduce disease progression.",
"   </p>",
"   <p>",
"    In areas of high prevalence of alpha-1 antitrypsin (AAT) deficiency, it is appropriate to screen all patients with COPD by obtaining an AAT serum level [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24425398\">",
"     'Laboratory'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6089?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Risk factors and risk reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263049556\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who present in mid or later life with dyspnea, cough, and sputum production, the differential diagnosis is broad (eg, heart failure, COPD, interstitial lung disease, thromboembolic disease) (",
"    <a class=\"graphic graphic_table graphicRef51974 \" href=\"UTD.htm?13/13/13533\">",
"     table 2",
"    </a>",
"    ). Typically, the finding of persistent airflow limitation on pulmonary function testing and the absence of radiographic features of heart failure or interstitial lung disease direct the clinician to a narrower differential of COPD, chronic obstructive asthma, bronchiectasis, tuberculosis, constrictive bronchiolitis, and diffuse panbronchiolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/6\">",
"     6",
"    </a>",
"    ]. Importantly, these conditions can commonly occur together, for example, patients with asthma may develop COPD and patients with COPD may have concurrent bronchiectasis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic obstructive asthma &ndash; In some patients with chronic asthma, a clear distinction from COPD is not possible. As an example, a patient, who has had atopic asthma since childhood and smoked cigarettes for 15 years in their twenties and thirties, could present in their fifties with a combination of asthma and COPD. The importance of recognizing the coexistence of these diseases is in devising a treatment plan that is adapted to reflect both underlying disease processes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"       \"Diagnosis of asthma in adolescents and adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic bronchitis with normal spirometry &ndash; A small portion of cigarette smokers have a chronic productive cough for three months in two successive years, but do not have airflow limitation on pulmonary function tests. They are not considered to have COPD, although they may develop COPD if they continue to smoke. Some treatments for COPD may improve their cough. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Interrelationships of COPD subtypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Central airway stenosis &ndash; Central airway stenosis can be caused by numerous benign and malignant processes and can mimic COPD with a slowly progressive dyspnea on exertion followed by dyspnea with minimal activity. Monophonic wheezing or stridor may be present. Symptoms are minimally improved by inhaled bronchodilator, if at all. A high index of suspicion is needed as conventional chest radiographs are rarely diagnostic. Though insensitive, flow volume loops can show the characteristic changes of central airway obstruction, frequently before abnormalities in the spirometric volumes are noted (",
"      <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef73686 \" href=\"UTD.htm?27/40/28302\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/64\">",
"       64",
"      </a>",
"      ]. A high resolution CT scan with three-dimensional reconstruction can be helpful. The gold standard for diagnosis is direct visualization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis and management of central airway obstruction\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchiectasis &ndash; Bronchiectasis, a condition of abnormal widening of the bronchi that is associated with chronic or recurrent infection, shares many clinical features with chronic obstructive pulmonary disease (COPD), including inflamed and easily collapsible airways, obstruction to airflow, and exacerbations characterized by increased dyspnea and sputum production. Bronchiectasis is suspected on the basis of prominent symptoms of cough and daily mucopurulent sputum production. The diagnosis is usually established clinically based on the characteristic cough and sputum production and the presence of bronchial wall thickening and luminal dilatation on chest computed tomographic (CT) scans. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heart failure &ndash; Heart failure is a common cause of dyspnea among middle-aged and older patients and some patients experience chest tightness and wheezing with fluid overload due to heart failure. Occasionally, airflow limitation is noted, although a restrictive pattern is more common. Heart failure is usually differentiated by the presence of fine basilar crackles, radiographic evidence of an increased heart size and pulmonary edema. The brain natriuretic peptide is typically increased in heart failure, but can also be increased during right heart strain from cor pulmonale. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"       \"Evaluation of the patient with suspected heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tuberculosis &ndash; In an area endemic for tuberculosis, the overall prevalence of airflow obstruction was 31 percent among those with a past history of tuberculosis compared with 14 percent among those without. This association was unchanged after adjustment for respiratory disease in childhood, smoking, and exposure to dust and smoke [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. Thus, tuberculosis is both a risk factor for COPD and a potential comorbidity [",
"      <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/6,11\">",
"       6,11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"       \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Constrictive bronchiolitis &ndash; Constrictive bronchiolitis, also known as bronchiolitis obliterans, is characterized by submucosal and peribronchiolar fibrosis that causes concentric narrowing of the bronchiolar lumen. Constrictive bronchiolitis is most commonly seen following inhalation injury, transplantation (eg, bone marrow, lung), or in the context of rheumatoid lung or inflammatory bowel disease (",
"      <a class=\"graphic graphic_table graphicRef58035 \" href=\"UTD.htm?9/57/10139\">",
"       table 4",
"      </a>",
"      ). Symptoms include progressive onset of cough and dyspnea associated with hypoxemia at rest or with exercise. Crackles may be present. Pulmonary function tests show a progressive and irreversible airflow limitation. Findings on inspiratory CT scan include centrilobular bronchial wall thickening, bronchiolar dilation, tree-in-bud pattern, and a mosaic ground-glass attenuation pattern. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link&amp;anchor=H6#H6\">",
"       \"Bronchiolitis in adults\", section on 'Constrictive bronchiolitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diffuse panbronchiolitis &ndash; Diffuse panbronchiolitis is predominantly seen in male nonsmokers of Asian descent. Almost all have chronic sinusitis. On pulmonary function testing, an obstructive defect is common, although a mixed obstructive-restrictive pattern may also be seen. Chest radiographs and high resolution CT scans show diffuse centrilobular nodular and linear opacities corresponding to thickened and dilated bronchiolar walls with intraluminal mucous plugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43769?source=see_link&amp;anchor=H11949013#H11949013\">",
"       \"Diffuse panbronchiolitis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine screening spirometry is generally not indicated for adults who have none of the features suggestive of COPD (eg, no dyspnea, cough, sputum production or progressive decline in activity), as asymptomatic mild airflow obstruction does not require treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Asymptomatic and nonsmoking subjects with mild airflow obstruction, but no history of asthma, do not have the same progressive decline in lung function that is observed among individuals who have a similar degree of airflow obstruction and are symptomatic or continue to smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, waiting for patients to report symptoms may miss a large number of patients who have COPD, as 20 percent of individuals with severe airway obstruction due to smoking or asthma will not report symptoms. Decrements in FEV",
"    <sub>",
"     1",
"    </sub>",
"    , even within the normal range, are associated with increased risk of acute cardiac events independent of age, gender, and smoking history [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/37\">",
"     37",
"    </a>",
"    ]. Thus, performance of spirometry seems reasonable whenever COPD is a diagnostic consideration. The diagnosis of COPD may alter management of concurrent conditions and may affect the approach to exercise. Exclusion of COPD can often contribute to clinical management as much as its diagnosis by leading to alternative diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines used the FEV",
"    <sub>",
"     1",
"    </sub>",
"    (expressed as a percentage of predicted) to stage disease severity. However, the FEV",
"    <sub>",
"     1",
"    </sub>",
"    only captures one component of COPD severity, and two patients with the same percent predicted FEV",
"    <sub>",
"     1",
"    </sub>",
"    can have a substantially different exercise tolerance and prognosis. Other aspects of disease, such as the severity of symptoms, risk of exacerbations, and the presence of comorbidities, are important to the patient&rsquo;s experience of the disease and prognosis and are included in newer staging systems, such as the revised GOLD classification [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/6,70\">",
"     6,70",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Several tools for evaluating symptom severity have been proposed. The GOLD guidelines suggest using instruments such as the modified Medical Research Council (mMRC) dyspnea scale (",
"    <a class=\"graphic graphic_table graphicRef86426 \" href=\"UTD.htm?11/62/12267\">",
"     table 5",
"    </a>",
"    ), the Clinical COPD Questionnaire (",
"    <a class=\"graphic graphic_table graphicRef86308 \" href=\"UTD.htm?11/35/11838\">",
"     table 6",
"    </a>",
"    ), or the COPD Assessment Tool (CAT) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/6,71-74\">",
"     6,71-74",
"    </a>",
"    ]. In our practice, we typically use the mMRC scale. The most widely used tool, the St. George's Respiratory Questionnaire (SGRQ), is a 76 item questionnaire that includes three component scores (ie, symptoms, activity, and impact on daily life) and a total score. While valuable for research purposes in patients with COPD, asthma, and bronchiectasis, it is too long and complicated for use in routine clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Gold guidelines suggest using a combination of an individual&rsquo;s symptoms, history of exacerbations, and FEV",
"    <sub>",
"     1",
"    </sub>",
"    to assess the exacerbation risk and guide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/6\">",
"     6",
"    </a>",
"    ]. Symptom severity is assessed using the modified Medical Research Council (mMRC) or COPD assessment test (CAT) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/6\">",
"     6",
"    </a>",
"    ]. The number of exacerbations in the previous 12 months can be used to predict future risk. A history of zero or one exacerbation in the past 12 months suggests a low future risk of exacerbations, while two or more exacerbations suggest a high future risk [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/6\">",
"     6",
"    </a>",
"    ]. The severity of lung function impairment is stratified based on the postbronchodilator FEV",
"    <sub>",
"     1",
"    </sub>",
"    , using the GOLD classification (",
"    <a class=\"graphic graphic_table graphicRef82690 \" href=\"UTD.htm?34/28/35275\">",
"     table 3",
"    </a>",
"    ). These three components are combined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk, less symptoms: Typically GOLD 1 or GOLD 2 (mild or moderate airflow limitation)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      0 to 1 exacerbation per year and mMRC grade 0 to 1 or CAT score &lt;10.",
"     </li>",
"     <li>",
"      Low risk, more symptoms: Typically GOLD 1 or GOLD 2 (mild or moderate airflow limitation)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      0 to 1 exacerbation per year and mMRC grade &gt;2 or CAT score &ge;10.",
"     </li>",
"     <li>",
"      High risk, less symptoms: Typically GOLD 3 or GOLD 4 (severe or very severe airflow limitation)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      &ge;2 exacerbations per year and mMRC grade 0 to 1 or CAT score &lt;10.",
"     </li>",
"     <li>",
"      High risk, more symptoms: Typically GOLD 3 or GOLD 4 (severe or very severe airflow limitation)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      &ge;2 exacerbations per year and mMRC grade &gt;2 or CAT score &ge;10.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other systems for assessing disease severity in the COPD patient have been proposed. The BODE index, which is calculated based on weight (BMI), airway obstruction (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ), dyspnea (mMRC dyspnea score), and exercise capacity (six-minute walk distance) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?22/50/23329?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), has been used to assess an individual&rsquo;s risk of death. This index provides better prognostic information than the FEV",
"    <sub>",
"     1",
"    </sub>",
"    alone and can be used to assess therapeutic response to medications, pulmonary rehabilitation therapy, and other interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/78-81\">",
"     78-81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35351?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions\", section on 'BODE index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other staging systems for COPD (eg, DOSE, ADO) have also been developed, but are not used routinely in clinical practice. The DOSE staging system comprises dyspnea, airflow obstruction, smoking status, and exacerbation frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/82\">",
"     82",
"    </a>",
"    ], while the ADO staging system combines age, dyspnea (by MRC scale), and airflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio is not used for staging because measurement of FVC becomes less reliable as the disease progresses (the long exhalations are difficult for the patients), thus making the ratio less accurate. Different clinical practice guidelines use different cut-off values, but most are similar to the GOLD staging system (",
"    <a class=\"graphic graphic_table graphicRef82690 \" href=\"UTD.htm?34/28/35275\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/14/30954/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35351?source=see_link&amp;anchor=H20085935#H20085935\">",
"     \"Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions\", section on 'Forced expiratory volume in one second'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/48/15107?source=see_link\">",
"       \"Patient information: Chronic bronchitis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24755?source=see_link\">",
"       \"Patient information: Medicines for chronic obstructive pulmonary disease (COPD) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as follows: \"Chronic obstructive pulmonary disease (COPD), a common preventable and treatable disease, is characterized by airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.\" (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Substantial overlap exists between COPD and the other disorders that cause airflow limitation (eg, emphysema, chronic bronchitis, asthma, bronchiectasis, bronchiolitis) as illustrated in the figure (",
"      <a class=\"graphic graphic_figure graphicRef66708 \" href=\"UTD.htm?35/52/36686\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Interrelationships of COPD subtypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common presentations of COPD include patients with few complaints, but an extremely sedentary lifestyle; patients with chronic, daily respiratory symptoms (eg, dyspnea on exertion, cough); and patients with recurrent acute exacerbations (eg, wheezing, cough, dyspnea). The physical examination of the chest varies with the severity of the COPD, but is often normal in mild disease (",
"      <a class=\"graphic graphic_table graphicRef53303 graphicRef61983 \" href=\"UTD.htm?41/42/42669\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of COPD should be considered and spirometry performed in all patients who report any combination of the following: dyspnea, chronic cough, or chronic sputum production, especially if there is a history of exposure to triggers of COPD (eg, tobacco smoke, occupational dust, indoor biomass smoke) or a family history of chronic lung disease (",
"      <a class=\"graphic graphic_table graphicRef50637 \" href=\"UTD.htm?41/57/42907\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pulmonary function tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      COPD is confirmed when a patient with compatible symptoms is found to have irreversible airflow limitation (ie, a post bronchodilator forced expiratory volume in one second",
"      <span class=\"nowrap\">",
"       [FEV",
"       <sub>",
"        1",
"       </sub>",
"       ]/forced",
"      </span>",
"      vital capacity [FVC] ratio less than 0.70 [or less than the lower limit of normal] and an FEV",
"      <sub>",
"       1",
"      </sub>",
"      &lt;80 percent predicted) and no alternative explanation for the symptoms and airflow obstruction. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pulmonary function tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In areas of high prevalence of alpha-1 antitrypsin (AAT) deficiency, all symptomatic adults with fixed airflow obstruction on spirometry should be tested for AAT deficiency with an AAT serum level. (See",
"      <a class=\"local\" href=\"#H24425398\">",
"       'Laboratory'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the evaluation of patients with COPD, chest radiography is typically performed to exclude alternative diagnoses, evaluate for comorbidities, or assess a change in symptoms that suggests a complication of COPD. Chest computed tomography is performed to evaluate abnormalities seen on the conventional chest radiograph, to exclude certain complications of COPD (eg, thromboembolic disease), or when a patient is being considered for lung volume reduction surgery. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The original FEV",
"      <sub>",
"       1",
"      </sub>",
"      -based GOLD staging system is shown in the table (",
"      <a class=\"graphic graphic_table graphicRef82690 \" href=\"UTD.htm?34/28/35275\">",
"       table 3",
"      </a>",
"      ). Although well recognized and commonly used, the GOLD staging system has been criticized for underestimating the importance of the extrapulmonary manifestations of COPD in predicting outcome. Other multidimensional staging systems (eg, GOLD combined assessment tool, BODE index) address this criticism (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?22/50/23329?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of COPD and strategies for smoking cessation are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"       \"Management of stable chronic obstructive pulmonary disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/1\">",
"      Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/2\">",
"      Gershon AS, Warner L, Cascagnette P, et al. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 2011; 378:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Chronic obstructive pulmonary disease among adults--United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/4\">",
"      Mini&ntilde;o AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl Vital Stat Rep 2011; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/5\">",
"      Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 2006; 367:1216.",
"     </a>",
"    </li>",
"    <li>",
"     Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Revised 2011. Global Initiative for Chronic Obstructive Lung Disease (GOLD). www.goldcopd.org (Accessed on March 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/7\">",
"      Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/8\">",
"      Rennard SI. COPD: overview of definitions, epidemiology, and factors influencing its development. Chest 1998; 113:235S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/9\">",
"      PIERCE JA, HOCOTT JB, EBERT RV. The collagen and elastin content of the lung in emphysema. Ann Intern Med 1961; 55:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/10\">",
"      Vlahovic G, Russell ML, Mercer RR, Crapo JD. Cellular and connective tissue changes in alveolar septal walls in emphysema. Am J Respir Crit Care Med 1999; 160:2086.",
"     </a>",
"    </li>",
"    <li>",
"     Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Executive summary 2006. Global Initiative for Chronic Obstructive Lung Disease (GOLD). file://www.goldcopd.org (Accessed on December 14, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/12\">",
"      McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011; 365:1567.",
"     </a>",
"    </li>",
"    <li>",
"     Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. file://www.ginasthma.org/local/uploads/files/GINA_Report_2012Feb13.pdf (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/14\">",
"      Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/15\">",
"      Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/16\">",
"      BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52 Suppl 5:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/17\">",
"      Obstructive lung disease. Med Clin North Am 1990; 74:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/18\">",
"      Rosenbloom J, Campbell EJ, Mumford R, et al. Biochemical/immunologic markers of emphysema. Ann N Y Acad Sci 1991; 624 Suppl:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/19\">",
"      Petty TL, Silvers GW, Stanford RE. Mild emphysema is associated with reduced elastic recoil and increased lung size but not with air-flow limitation. Am Rev Respir Dis 1987; 136:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/20\">",
"      O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/21\">",
"      Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest 2000; 117:251S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/22\">",
"      Aoshiba K, Nagai A. Differences in airway remodeling between asthma and chronic obstructive pulmonary disease. Clin Rev Allergy Immunol 2004; 27:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/23\">",
"      Baraldo S, Turato G, Badin C, et al. Neutrophilic infiltration within the airway smooth muscle in patients with COPD. Thorax 2004; 59:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/24\">",
"      Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol 2003; 112:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/25\">",
"      Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/26\">",
"      Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/27\">",
"      Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/28\">",
"      Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/29\">",
"      Kuempel ED, Wheeler MW, Smith RJ, et al. Contributions of dust exposure and cigarette smoking to emphysema severity in coal miners in the United States. Am J Respir Crit Care Med 2009; 180:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/30\">",
"      Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011; 139:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/31\">",
"      Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155:179.",
"     </a>",
"    </li>",
"    <li>",
"     Simel D, Rennie D. The rational clinical examination: Evidence-based clinical diagnosis, McGraw Hill.  (Ed), New York 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/33\">",
"      Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000; 160:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/34\">",
"      Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/35\">",
"      Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002; 20:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/36\">",
"      Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011; 37:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/37\">",
"      Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/38\">",
"      Eisner MD, Blanc PD, Yelin EH, et al. COPD as a systemic disease: impact on physical functional limitations. Am J Med 2008; 121:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/39\">",
"      Kjensli A, Falch JA, Ryg M, et al. High prevalence of vertebral deformities in COPD patients: relationship to disease severity. Eur Respir J 2009; 33:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/40\">",
"      Puente-Maestu L, P&eacute;rez-Parra J, Godoy R, et al. Abnormal mitochondrial function in locomotor and respiratory muscles of COPD patients. Eur Respir J 2009; 33:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/41\">",
"      Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/42\">",
"      Swallow EB, Barreiro E, Gosker H, et al. Quadriceps muscle strength in scoliosis. Eur Respir J 2009; 34:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/43\">",
"      Badgett RG, Tanaka DJ, Hunt DK, et al. Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? Am J Med 1993; 94:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/44\">",
"      Lemyze M, Bart F. Hoover sign. CMAJ 2011; 183:E133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/45\">",
"      Garcia-Pachon E, Padilla-Navas I. Frequency of Hoover's sign in stable patients with chronic obstructive pulmonary disease. Int J Clin Pract 2006; 60:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/46\">",
"      American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/47\">",
"      Shirtcliffe P, Weatherall M, Marsh S, et al. COPD prevalence in a random population survey: a matter of definition. Eur Respir J 2007; 30:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/48\">",
"      Vaz Fragoso CA, Gill TM, McAvay G, et al. Use of lambda-mu-sigma-derived Z score for evaluating respiratory impairment in middle-aged persons. Respir Care 2011; 56:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/49\">",
"      Vaz Fragoso CA, Concato J, McAvay G, et al. Respiratory impairment and COPD hospitalisation in older persons: a competing risk analysis. Eur Respir J 2012; 40:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/50\">",
"      Vaz Fragoso CA, Gill TM, McAvay G, et al. Respiratory impairment in older persons: when less means more. Am J Med 2013; 126:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/51\">",
"      Mannino DM, Diaz-Guzman E. Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. Chest 2012; 141:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/52\">",
"      Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/53\">",
"      Swanney MP, Jensen RL, Crichton DA, et al. FEV(6) is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. Am J Respir Crit Care Med 2000; 162:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/54\">",
"      Demir T, Ikitimur HD, Koc N, Yildirim N. The role of FEV6 in the detection of airway obstruction. Respir Med 2005; 99:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/55\">",
"      Vandevoorde J, Verbanck S, Schuermans D, et al. FEV1/FEV6 and FEV6 as an alternative for FEV1/FVC and FVC in the spirometric detection of airway obstruction and restriction. Chest 2005; 127:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/56\">",
"      Kelly AM, McAlpine R, Kyle E. How accurate are pulse oximeters in patients with acute exacerbations of chronic obstructive airways disease? Respir Med 2001; 95:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/57\">",
"      Matthay RA, Niederman MS, Wiedemann HP. Cardiovascular-pulmonary interaction in chronic obstructive pulmonary disease with special reference to the pathogenesis and management of cor pulmonale. Med Clin North Am 1990; 74:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/58\">",
"      Klein JS, Gamsu G, Webb WR, et al. High-resolution CT diagnosis of emphysema in symptomatic patients with normal chest radiographs and isolated low diffusing capacity. Radiology 1992; 182:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/59\">",
"      Park KJ, Bergin CJ, Clausen JL. Quantitation of emphysema with three-dimensional CT densitometry: comparison with two-dimensional analysis, visual emphysema scores, and pulmonary function test results. Radiology 1999; 211:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/60\">",
"      Mair G, Miller JJ, McAllister D, et al. Computed tomographic emphysema distribution: relationship to clinical features in a cohort of smokers. Eur Respir J 2009; 33:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/61\">",
"      Hasegawa M, Nasuhara Y, Onodera Y, et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/62\">",
"      Grydeland TB, Dirksen A, Coxson HO, et al. Quantitative computed tomography: emphysema and airway wall thickness by sex, age and smoking. Eur Respir J 2009; 34:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/63\">",
"      Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007; 147:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/64\">",
"      Modrykamien AM, Gudavalli R, McCarthy K, et al. Detection of upper airway obstruction with spirometry results and the flow-volume loop: a comparison of quantitative and visual inspection criteria. Respir Care 2009; 54:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/65\">",
"      Menezes AM, Hallal PC, Perez-Padilla R, et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J 2007; 30:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/66\">",
"      Jordan TS, Spencer EM, Davies P. Tuberculosis, bronchiectasis and chronic airflow obstruction. Respirology 2010; 15:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/67\">",
"      U.S. Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 148:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/68\">",
"      Lin K, Watkins B, Johnson T, et al. Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 148:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/69\">",
"      de Marco R, Accordini S, Ant&ograve; JM, et al. Long-term outcomes in mild/moderate chronic obstructive pulmonary disease in the European community respiratory health survey. Am J Respir Crit Care Med 2009; 180:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/70\">",
"      Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012; 186:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/71\">",
"      Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT&trade;) scores. BMC Pulm Med 2011; 11:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/72\">",
"      Kelly JL, Bamsey O, Smith C, et al. Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients. Respiration 2012; 84:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/73\">",
"      van der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003; 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     COPD Assessment Test (CAT). file://www.catestonline.org (Accessed on September 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/75\">",
"      Weatherall M, Marsh S, Shirtcliffe P, et al. Quality of life measured by the St George's Respiratory Questionnaire and spirometry. Eur Respir J 2009; 33:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/76\">",
"      Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/77\">",
"      Wilson CB, Jones PW, O'Leary CJ, et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997; 156:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/78\">",
"      Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/79\">",
"      Celli BR. Change in the BODE index reflects disease modification in COPD: lessons from lung volume reduction surgery. Chest 2006; 129:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/80\">",
"      Puhan MA, Mador MJ, Held U, et al. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 2008; 32:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/81\">",
"      Cote CG, Pinto-Plata VM, Marin JM, et al. The modified BODE index: validation with mortality in COPD. Eur Respir J 2008; 32:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/82\">",
"      Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009; 180:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/14/30954/abstract/83\">",
"      Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374:704.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1455 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30954=[""].join("\n");
var outline_f30_14_30954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H263049240\">",
"      COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H263049277\">",
"      Chronic bronchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H263049416\">",
"      Emphysema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H263049549\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Interrelationships of COPD subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18807517\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18484273\">",
"      Airways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18484281\">",
"      Lung parenchyma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18484288\">",
"      Pulmonary vasculature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20447432\">",
"      Smoking and inhalational exposure history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Symptoms and pattern of onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24425163\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24425398\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27742482\">",
"      - Spirometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18484580\">",
"      - Lower limit of normal FEV1/FVC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18484573\">",
"      - Forced expiratory volume in six seconds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1675515\">",
"      - Peak expiratory flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27742489\">",
"      - Lung volumes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27742496\">",
"      - Diffusing capacity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H263050352\">",
"      - Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H263049556\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1455\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1455|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?2/57/2974\" title=\"algorithm 1\">",
"      Asthma and COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1455|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/47/40693\" title=\"diagnostic image 1\">",
"      Panacinar emphysema PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/10/27813\" title=\"diagnostic image 2\">",
"      Chest x-ray emphysema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/54/21349\" title=\"diagnostic image 3\">",
"      Giant bilateral bullae PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/55/40819\" title=\"diagnostic image 4\">",
"      Centrilobular emphysema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/37/21074\" title=\"diagnostic image 5\">",
"      Pulmonary histiocytosis X CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/55/22386\" title=\"diagnostic image 6\">",
"      Panlobular emphysema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/6/36961\" title=\"diagnostic image 7\">",
"      Paraseptal emphysema I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/6/5220\" title=\"diagnostic image 8\">",
"      Paraseptal emphysema II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1455|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/52/36686\" title=\"figure 1\">",
"      COPD Venn diagram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/38/31341\" title=\"figure 2\">",
"      Chronic respiratory acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/44/42691\" title=\"figure 3\">",
"      Expected compensation ranges for simple acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/31/35325\" title=\"figure 4\">",
"      Flow volume loops in airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/40/28302\" title=\"figure 5\">",
"      Upper airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1455|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/52/8005\" title=\"picture 1\">",
"      Leukocyte infiltration COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1455|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/20/44364\" title=\"table 1A\">",
"      Diagnosis of COPD I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/17/23836\" title=\"table 1B\">",
"      Diagnosis of COPD - PFTs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/13/13533\" title=\"table 2\">",
"      Differential dx COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/28/35275\" title=\"table 3\">",
"      Severity of airflow limitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/57/10139\" title=\"table 4\">",
"      Constrictive bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/62/12267\" title=\"table 5\">",
"      MMRC dyspnea scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/35/11838\" title=\"table 6\">",
"      Clinical COPD Questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/57/42907\" title=\"table 7\">",
"      Key indicators diagnosis COPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?22/50/23329?source=related_link\" title=\"calculator 1\">",
"      Calculator: BODE Index for COPD survival prediction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35351?source=related_link\">",
"      Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6089?source=related_link\">",
"      Chronic obstructive pulmonary disease: Risk factors and risk reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43769?source=related_link\">",
"      Diffuse panbronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36454?source=related_link\">",
"      Dynamic hyperinflation in patients with COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8136?source=related_link\">",
"      Evaluation and medical management of giant bullae in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=related_link\">",
"      Lung volume reduction surgery in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/48/15107?source=related_link\">",
"      Patient information: Chronic bronchitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24755?source=related_link\">",
"      Patient information: Medicines for chronic obstructive pulmonary disease (COPD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_14_30955="Classification tracheomalacia";
var content_f30_14_30955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of adult tracheomalacia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Primary or Congenital",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Genetic, such as polychondritis (See also Pediatric table)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Idiopathic \"Giant Trachea\" or Mounier-Kuhn",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Secondary or Acquired",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Post-traumatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Post intubation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Post tracheostomy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       External chest trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Post lung transplantation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Emphysema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Chronic Infection/Bronchitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Chronic Inflammation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Relapsing Polychondritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Chronic External Compression of the Trachea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Malignancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Benign Tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cysts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Abscesses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Aortic aneurysm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vascular Rings, previously undiagnosed in childhood",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30955=[""].join("\n");
var outline_f30_14_30955=null;
var title_f30_14_30956="Spitz nevi conventional";
var content_f30_14_30956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of conventional Spitz nevi",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Architecture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diameter &lt;5 to 6 mm*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symmetric outline*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sharp lateral circumscription*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regular pattern of epidermal hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maturation with depth in dermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zonation across the horizontal axis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wedge-shaped configuration within dermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orderly nondisruptive infiltration of collagen by melanocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cytology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spindle or epithelioid cell type*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uniform population of cells*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low nuclear-to-cytoplasmic ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opaque or ground glass cytoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nuclei with open, delicate chromatin pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uniform nucleoli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rare pleomorphism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other helpful diagnostic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitotic rate &lt;2/mm",
"        <sup>",
"         2",
"        </sup>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absent or rare mitoses in deep dermis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of atypical mitoses*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irregular contours of growth at deep margin*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kamino bodies*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mononuclear or multinucleate giant cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimal central pagetoid upward scatter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Junctional clefts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of cohesion between cells (retraction spaces)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perivascular or diffuse inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Superficial distribution of pigmentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Telangiectasia and edema",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Most helpful features.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted by permission from: Macmillan Publishers Ltd: Modern Pathology. Barnhill RL. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment. Mod Pathol 2006; 19 Suppl 2:S21. Copyright &copy; 2006.",
"     <a href=\"file://www.nature.com/modpathol/index.html\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.nature.com/modpathol/index.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30956=[""].join("\n");
var outline_f30_14_30956=null;
var title_f30_14_30957="Commonly ingested nontoxic plants and minimally toxic plants";
var content_f30_14_30957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=72\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=72\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly ingested nontoxic plants and minimally toxic plants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Nontoxic plants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Abelia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            African daisy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            African violet",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aralia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aspidistra",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aster",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Baby's tears",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bachelor buttons",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Begonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bird's nest fern",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Blood leaf plant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Boston ferns",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bougainvillea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            California holly",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Camelia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Christmas cactus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dahlia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Daisies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dandelion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Day lily",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Easter lily",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Echeveria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eugenia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gardenia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hedge apples",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Honeysuckle",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Impatiens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Jade plant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Magnolia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Marigold",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Petunia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prayer plant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyracantha (leaf or flower)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rose",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Schefflera",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spider plant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Swedish ivy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Violets",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wandering Jew",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Weeping fig",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Weeping willow",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wild onion",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Minimally toxic plants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Mucosal irritation*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dieffenbachia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Elephant ear",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Jack-in-the-pulpit",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Peace lily",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Philodendron",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Skunk cabbage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Minor gastrointestional irritation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Amaryllis bulb",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            American mistletoe berries",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Daffodil bulb",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Holly berries",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Poinsettia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pyracantha berries",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Rarely, significant mucosal irritation with drooling, dysphagia, and/or airway obstruction can occur.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Osterhoudt KC, Burns Ewald M, Shannon M, Henretig FM. Toxicologic emergencies. In: Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30957=[""].join("\n");
var outline_f30_14_30957=null;
var title_f30_14_30958="Glucose and insulin concentrations after prolonged fast";
var content_f30_14_30958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plasma glucose and insulin concentrations after a prolonged fast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 396px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between plasma glucose and insulin concentrations in normal subjects and patients with insulinoma after a prolonged fast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Service FJ. Diagnostic approach to adults with hypoglycemic disorders. Endocrinol Metab Clin North Am 1999; 28:519.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30958=[""].join("\n");
var outline_f30_14_30958=null;
var title_f30_14_30959="Prenatal ultrasound renal agenesis";
var content_f30_14_30959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound bilateral renal agenesis with adrenals in the renal fossa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral renal agenesis, adrenals in the renal fossas seen on transverse view (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_14_30959=[""].join("\n");
var outline_f30_14_30959=null;
